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Abstract 
We tested 6 single nucleotide polymorphisms (SNPs) associated with obesity from genome wide 
association studies for their association with physical activity (PA).  Healthy European-American 
women (n=265) and men (n=230) (23.5±0.3yr, 24.6±0.2kg•m-2) were genotyped for MC4R 
(rs17782313), FTO (rs9939609), TMEM18 (rs6548238), NEGR1 (rs2815752), SH2B1 (rs7498665), and 
KCTD15 (rs11084753), and completed the Paffenbarger PA Questionnaire. We examined gene 
interactions by summing the number of obesity effect alleles. RESULTS: Normal weight subjects with 
MC4R T expended 1981.2±741.7kcal∙wk-1 less than non-carriers in total PA (p=0.008), 1825.9±650.2 
kcal∙wk-1 less in sports/recreation (p=0.027), and 1231.3±552.7 kcal∙wk-1 less in vigorous PA (p=0.005). 
Subjects with TMEM18 C expended 1216.5±356.3kcal∙wk-1 less than non-carriers in moderate PA 
(p=0.001). Overweight men homozygous for FTO T expended 871.4±397.1kcal∙wk-1 less than A carriers 
in vigorous PA (p=0.031). Subjects homozygous for SH2B1 G spent 4.8±1.9hr∙wk-1 less than non-
carriers in moderate PA (p=0.013), and 5.6±2.2hr∙wk-1 more in light PA. Women homozygous for 
NEGR1 G spent 7.6±2.7hr∙wk-1 less than A carriers in moderate PA (p=0.006). Overweight subjects 
homozygous for KCTD15 A spent 14.2 ±4.8hr∙wk-1 more than G carriers in sitting (p=0.004). Men with 
5-6 (n=173) obesity effect alleles expanded 1082.3±447.2kcal∙wk-1 more in sports/recreation (p=0.049) 
and 663.8±418.1kcal∙wk-1 more in vigorous PA (p=0.049) than men with 7-10 (n=131), with similar 
non-significant trends noted for 1-4 (n=153) obesity effect alleles (p>0.05).  CONCLUSION: The 
genotype differences in energy expenditure that equate to 11-25 lb∙yr-1 have important implications for 
weight maintenance. The mechanisms explaining these associations appear to have a common central 
neural influence that should be explored further. 
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Chapter 1 - Introduction 
Background and Significance 
Obesity is an epidemic in the Unites States (U.S.) with 69% of adults being either overweight 
[body mass index (BMI)>25kg∙m-2] or obese (BMI>30kg∙m-2). Between 1980 and 2010 in the 
U.S., the prevalence of the obesity within the adult population has grown from 15.0% to 35.7% 
(31). If the current trends proceed at this pace, by 2030, all 50 states could have adult obesity 
rates of at least 44%, 39 states would have rates of 50% or more, and 13 states would have more 
than 60% of adults with obesity (81). Obesity is associated with significant increases in both 
mortality and morbidity (3). It is estimated that there are 4 million deaths attributable to obesity 
in the U.S. each year (57). The most important and common comorbidities resulting from obesity 
are hypertension, type 2 diabetes mellitus, hyperlipidemia, and coronary artery disease (38). In 
addition, abdominal obesity is associated with metabolic syndrome (23). Other comorbidities of 
obesity are asthma, non-alcoholic fatty liver disease, polycyclic ovary disease, gall bladder 
disease, and several cancers (5, 9, 10, 16, 33, 59, 65, 68). The U.S. medical service system 
spends $147 billion per year for direct medical costs related to overweight and obesity, which 
accounts for 9% of the total U.S. health-care expenditure (28). According to a national survey 
data (National Health and Nutrition Examination Study) from 1970s and 2004, by 2030, the total 
health-care costs attributable to obesity and overweight are projected to $ 861-957 billion 
accounting for 16–18% of total U.S. health-care expenditure (83). 
 To mitigate this public health epidemic, the American College of Sports Medicine 
(ACSM) (25), American Heart Association (AHA), and the U.S. Department of Health and 
Human Services (79) advocate physical activity (PA) for weight loss and successful long-term 
weight maintenance. Habitual PA is bodily movement involving major muscle groups resulting 
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in caloric expenditure (17). The ACSM recommends 150 to 250 min∙wk-1 of moderate intensity 
PA for weight loss, and even greater amounts of PA (>250 min∙wk-1) for weight maintenance 
(25).  The U.S. Department of Health and Human Services (62) examined 4 randomized trials 
that investigated the influence of aerobic training on weight change. These studies (37, 55, 70, 
73) ranged in duration from 8 to 16 months, and the PA levels ranged from 180-360 min·wk
-1
 
performed at moderate to vigorous intensity. Subject included men and women from 40-75 years 
whose weight ranged from normal to overweight and obese. Typical weight losses were 2.2 to 
6.6 lb.  Of note, although the National Heart, Lung, and Blood Institute (NHLBI) Guidelines (62) 
recommend a minimum weight loss of 10%, beneficial improvements in chronic disease risk 
factors have been reported with as little as 2–3% of weight loss (24, 30, 43, 77). In addition, 
evidence of a dose-response relationship was clear; those doing the greatest amount of PA 
achieved the greatest weight losses.  
  One of the significant benefits of PA lies in its role in successful long-term weight 
maintenance after initial weight loss (85). Wing et al. (85) examined 4,000 members of the 
National Weight Control Registry who had lost an average of 33 lbs and maintained the weight 
lost for more than 5 years. To maintain their weight loss, members reported engaging in high 
levels of PA (approximately 1 h/d); eating a low-calorie, low-fat diet; eating breakfast regularly; 
self-monitoring weight; and maintaining a consistent eating pattern across weekdays and 
weekends. As shown, scientific evidence has proven that PA is effective in weight loss and 
weight maintenance after weight loss, and thereby health agencies and government endorse PA 
as a non-pharmaceutical treatment to address the current obesity epidemic.  
  Paradoxically, most people do not meet the recommended amount of PA level despite of 
well-known health benefits of PA. Less than half of U.S. adults meet the minimum 
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recommendations for PA as set by the ACSM and AHA (25). Moreover, about 24% of 
Americans do not participate in any leisure time PA (17). This low level of PA and sedentary 
lifestyle is also a serious public health issue. According to World Health Organization (WHO) 
(86), physical inactivity has been identified as the fourth leading risk factor for global mortality 
(6% of deaths globally), followed by high blood pressure (13%), tobacco use (9%) and high 
blood glucose (6%). Thus, identifying the determinants of the PA participation is critical, as it 
will yield relevant information to address the public health burdens of physical inactivity and 
obesity. Notably, understanding why people are physically active or inactive can contribute to 
evidence-based planning of public health interventions because effective programs targets factors 
known to cause inactivity (64).  
 
Purpose of the Study 
One of the longest debates in Western intellectual history is the relative influence of genetic and 
environmental factors on human behavioral differences, the so-called nature-nurture debate (22). 
Habitual PA, which also is a behavior that varies among individuals, is regulated or governed 
primarily by environmental factors, genetic factors, and interaction between both (8). Research 
into correlates (factors associated with) and determinants (those with a causal relationship) of PA 
has burgeoned in the past two decades, and it has shown that PA is influence by numerous 
factors such as psychological factors (e.g. cognition, beliefs, and motivation), built environment 
(e.g. availability of facilities), social environment (e.g. seeing others active), and biological 
factors (e.g. genetic factor).  Recent studies have identified genetic factors contributing to the 
propensity to be physically active (48-50, 78).  Yet, little is known about potential genetic 
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regulators of PA. Therefore, the purpose of this study is to identify genetic variants that 
associate with PA that have already been identified to associate with obesity. 
 
Genetics of Obesity and Physical Activity 
Obesity occurs most often when energy intake chronically exceeds energy expenditure (6). 
Similarly, as one of the expected phenotypic outcomes of being physically inactive is gaining 
weight, obesity genes may be reasonable candidate genes to investigate whether they associate 
with PA. Until recently, obesity was considered to be the outcome that is solely generated from 
obesogenic environment in which encourages excessive caloric intake and a sedentary life style 
(6). However, there are multiple lines of evidence reporting the genetic predisposition on the 
development of obesity (11, 13, 20, 52, 53, 61, 71, 74). The studies report that the heredity 
accounts for 37-78% of the variance in several measures of body composition including BMI, 
weight, and waist circumference. Bouchard (12) has categorized obesity genes in 5 groups in 
terms of biological function of the proteins the genes code for. They are, 1) a thrifty (low 
metabolic rate), 2) a hyperphagic (impaired appetite), 3) a low lipid oxidation (burn less fat), 4) 
an adipogenesis (accumulate more fat), 5) and a sedentary (physically inactive) (12).  
The sedentary gene codes for a protein that functions to modulate our propensity to be 
less active and sedentary, and in turn predisposes the individual to obesity (12).  Twin and family 
studies have shown that genetic factors contribute to variation in reported daily PA levels, with 
heritability estimates ranging from small (h
2
 <30%) (29, 32, 56, 69) to moderate (h
2
=30–65%), 
(14, 15, 26, 40, 54) to high (h
2
=78%) (1). The large heterogeneity might be explained by the 
large ranges in age within and between studies, the accuracy with which daily PA is assessed, 
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and study design (39). Regardless, these studies suggest the genetic influence on PA 
participation.  
All humans have almost the same sequence of 3 billion DNA bases (A,C,G, or T) 
distributed between their 23 pairs of chromosomes. But at certain locations of nucleotide bases 
there are mutations, and these variations are called single nucleotide polymorphism (SNP). To 
classify a variation as a SNP it should occur in at least 1% of the population. Although this 
mutation does not necessarily express functional phenotype, SNPs are responsible for over 80% 
of the variation between two individuals. Accordingly, SNPs are often used to identify 
association between genetic variants (i.e. SNP) and interest of phenotype (i.e. BMI or PA).  
Since PA is a critical component of energy balance, it is not surprising that many of the 
genetic variants associated with obesity have also been associated PA. Previously, Walsh et al. 
(82) reported leptin and leptin receptor genetic variants, which are renowned obesity genes that 
initiated the research in genetics of obesity (87), associate with habitual PA among European-
American adults (men=111, women=131, 23.4 ± 5.4 yr, 24.4 ± 4.6 kg·m
-2
) in Functional Single 
Nucleotide Polymorphisms Associated with Human Muscle Size and Strength (FAMuSS, NIH 
R01 NS40606-02) cohort. Leptin is an adipocyte-derived cytokine that can act in the brain to 
suppress feeding and maintain energy homeostasis. Similarly, Fat mass and obesity-associated 
gene (FTO; rs9939609) also has been shown to associate with PA as well as other obesity 
phenotypes (i.e. BMI, weight, waist circumference) (34, 36). Cecil et al. (18) examined if FTO 
(rs9939609) associates with adiposity, food intake, and energy expenditure in 71 Scottish 
children, 4 to 10 years of age, and observed children with the A allele being more physically 
active compared to non-carriers. As shown, it is evident that PA is inheritable and SNPs 
associated with obesity are also likely to associate with PA. Nonetheless, it still remains largely 
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unknown how the protein products from these genes affect PA level. What researchers are 
speculating from functional studies in PA is that these genes may affect PA level via neural 
influence on brain. 
Charney et al., noted that genes particularly prevalent in the human brain are likely 
relevant for a good deal of human behavior (19). Thus, we can speculate that obesity genes that 
code for proteins that are expressed in brain or neural pathways may govern certain behavior (e.g. 
eating or PA) that predisposes individuals to obesity. In the same way, evidence from human and 
animal studies (42, 46, 47, 76) indicates that intrinsic biological processes such as central 
nervous system (CNS) mechanisms might regulate daily PA. That is, reward systems, 
particularly the dopaminergic system, will be activated in individuals with above-average 
exercise abilities, those who crave PA, and those who feel rewarded by accomplishing PA (8). 
Dopamine functions in the control of motor movement (63), reward (66), learning, motivation 
(58), and emotion (67). As the dopamine system is involved in motivating and rewarding 
behavior that involves motor control, it would be a probable candidate biological system to 
modulate voluntary PA. As such, PA candidate genes might be part of the reward systems (21) in 
brain, and thereby studies that examined the regulation of PA have mainly focused on genes that 
constitute the dopaminergic pathway (4, 41, 88). Taken together, obesity genes that have impact 
on the dopaminergic pathway would be biologically plausible to associate with PA. 
  In 2012, Fall et al. conducted systematic review of SNPs reported to associate with 
obesity phenotypes in GWAS (27). They reported 99 genetic variants that showed association 
with obesity phenotypes in GWAS. Among 99 SNPs, FAMuSS study had genotype information 
for 6 SNPs: FTO (rs9939609), Melanocortin 4 receptor (MC4R; T2745C; rs17782313), 
Transmembrane protein 18 (TMEM18; rs6548238), Neuronal growth regulator 1 (NEGR1; 
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rs2815752), Src homology 2 B adapter protein 1 (SH2B1; Thr484Ala; rs7498665), and 
Potassium channel tetramerisation domain containing 15 (KCTD15; rs11084753). 
Willer et al. measured the expression of the genes nearest to their best SNP association 
signals in a panel of different human tissues in order to provide additional data on where these 
genes may function. They found that all genes were highly expressed in the brain and/or 
hypothalamus where energy homeostasis is regulated. It is noteworthy that all six SNPs in our 
study are categorized as hyperphagic genes (impaired appetite) according to Bouchard’s 
classification as they were all previously reported to associate with eating behavior (7, 18, 45, 
60). To date, there are no studies that examine if NEGR1, KCTD15, SH2B1, and TMEM18 
associate with PA in humans. However, NEGR1 and its association with PA have been examined 
with mice (44). Taken together, the fact that all SNPs are expressed in hypothalamus and 
previous association with behavior that affects energy balance (i.e. eating) provides biological 
rationale that these SNPs would likely to associate with PA, which is another form of behavior 
that can affect energy imbalance and predispose individual to obesity.   
In summary, despite the critical role of PA in weight loss and weight maintenance, little 
is known about specific genes that affect an individuals’ habitual PA level. However, previous 
studies indicate that several genes, such as LEPTIN and FTO, identified to be associated with 
obesity have also been associated with PA. Further, genetic variants associate with behavior 
related to obesity (e.g. eating or PA) are likely to expressed in brain. Thus, obesity-related 
genetic variants that are expressed in neural pathway would be biologically plausible candidate 
genes to investigate their association with PA. 
 
Specific Aim and Hypothesis 
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 As shown many of the genes identified to be associated with overweight and obesity have also 
been associated with PA (18, 82). To date, there are 99 genetic variants reported to be associated 
with the obesity phenotype in genome wide association studies (GWAS) (27). The methods used 
in the proposed research are based on the ‘Functional Single nucleotide polymorphisms 
Associated with Human Muscle Size and Strength (FAMuSS, NIH R01 NS40606-02)’ dataset. 
Therefore, the specific aim of present study is to examine 99 genetic variants identified to be 
associated with overweight and obesity in GWAS and their associations with PA in FAMuSS 
cohort. We hypothesize that SNPs associated with overweight and obesity also associate with 
PA and these include FTO (rs9939609), MC4R (rs17782313), TMEM18 (rs6548238), SH2B1 
(rs7498665), KCTD15 (rs11084753), NEGR1 (rs2815752). Although GWAS have shown strong 
associations between obesity and gene loci (34, 51, 72, 84), these loci explain no more than 2% 
of the individual variation in the susceptibility of obesity (84). Therefore, the secondary aim of 
present study is to assess the overall effect or gene-gene interaction status of 6 SNPs on PA level. 
In order to assess the epistatic or gene-gene interactions on habitual PA and BMI, we created a 
genotype combination score based upon previous GWAS obesity effect alleles reported in the 
literature (27)). We hypothesize that as the number of obesity effect allele increase, PA level 
would decrease and BMI would increase in a dose response manner. 
 
Limitations 
This study has several limitations. Habitual PA is a complex behavior that is likely influenced by 
psychological factors, social and built environment, other clinical information, and many genes 
other than our six SNPs through multiple pathways (8). Also, this study was not designed to 
obtain mechanistic data. Additionally, PA data were collected via questionnaire, thus exposing 
 9 
 
the possibility of subject recall or social desirability bias. However, the Paffenbarger PA 
questionnaire has been widely validated in similar populations to the present study and is 
considered an accurate method of leisure time PA in adults (2).  
  
Strengths 
This investigation is a subset of the FAMuSS study which is the largest study that has 
investigated candidate genes associated with muscle performance, and the first study to 
specifically investigate obesity-related SNPs associations with PA (75). Furthermore, FAMuSS 
meets the criteria outlined by Hagberg et al. (35) that are necessary for conducting exercise 
genomics studies including a large sample size, a well-structured exercise intervention with 
stringent assessment of phenotypes, and quality control of genotyping. In addition, heritability of 
PA varies across the lifespan. PA is more heritable for young adults and tends to decrease with 
age (80). Therefore, as ~75% of the FAMuSS subjects age ranged from 18 to 25, it is likely to 
exhibit a high level of heritability. 
   
Significance of the Study 
 Despite its crucial role in weight reduction, the genetic basis for PA remains largely unknown. If 
we find significant genetic influences on PA, we will prove our hypothesis that PA associates 
with SNPs associated with overweight and obesity. As we are one of the few studies examining 
the genetic basis of PA, this study can yield crucial data for future investigation of the genetic 
basis of PA. Genotype may influence PA, yet clinicians still use a generic approach in 
recommending PA to treat obesity. In this sense, our findings will be an important step toward 
providing clinicians with new knowledge about the genetic and biological basis of PA.    
 10 
 
References 
1. Aaltonen S, Ortega-Alonso A, Kujala UM, Kaprio J. A longitudinal study on genetic and 
environmental influences on leisure time physical activity in the Finnish Twin Cohort. Twin Res 
Hum Genet. 2010; 13(5):475-81. 
2. Albanes D, Conway JM, Taylor PR, Moe PW, Judd J. Validation and comparison of eight 
physical activity questionnaires. Epidemiology. 1990; 1(1):65-71. 
3. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to 
obesity in the United States. JAMA. 1999; 282(16):1530-8. 
4. Baik JH, Picetti R, Saiardi A, et al. Parkinsonian-like locomotor impairment in mice lacking 
dopamine D2 receptors. Nature. 1995; 377(6548):424-8. 
5. Barden A. Pre-eclampsia: contribution of maternal constitutional factors and the consequences 
for cardiovascular health. Clin Exp Pharmacol Physiol. 2006; 33(9):826-30. 
6. Baron RB. Nutritional Disorders. In: Papadakis MA, McPhee,S.J.,  Rabow MW, editors. 
CURRENT Medical Diagnosis and Treatment. 51st ed. New York: McGrawHill; 2013, p. 
http://www.accessmedicine.com/content.aspx?aID=16152. Accessed May 1, 2013. 
7. Bauer F, Elbers CC, Adan RA, et al. Obesity genes identified in genome-wide association 
studies are associated with adiposity measures and potentially with nutrient-specific food 
preference. Am J Clin Nutr. 2009; 90(4):951-9. 
 11 
 
8. Bauman AE, Reis RS, Sallis JF, Wells JC, Loos RJ, Martin BW. Correlates of physical 
activity: why are some people physically active and others not? Lancet. 2012; 380(9838):258-71. 
9. Bianchini F, Kaaks R, Vainio H. Weight control and physical activity in cancer prevention. 
Obes Rev. 2002; 3(1):5-8. 
10. Bodnar LM, Ness RB, Harger GF, Roberts JM. Inflammation and triglycerides partially 
mediate the effect of prepregnancy body mass index on the risk of preeclampsia. Am J Epidemiol. 
2005; 162(12):1198-206. 
11. Borjeson M. The aetiology of obesity in children. A study of 101 twin pairs. Acta Paediatr 
Scand. 1976; 65(3):279-87. 
12. Bouchard C. The biological predisposition to obesity: beyond the thrifty genotype scenario. 
Int J Obes. 2007; 31(9):1337-9. 
13. Bouchard C, Rice T, Lemieux S, Despres JP, Perusse L, Rao DC. Major gene for abdominal 
visceral fat area in the Quebec Family Study. Int J Obes Relat Metab Disord. 1996; 20(5):420-7. 
14. Cai G, Cole SA, Butte N, et al. A quantitative trait locus on chromosome 18q for physical 
activity and dietary intake in Hispanic children. Obesity. 2006; 14(9):1596-604. 
15. Carlsson S, Andersson T, Lichtenstein P, Michaelsson K, Ahlbom A. Genetic effects on 
physical activity: results from the Swedish Twin Registry. Med Sci Sports Exerc. 2006; 
38(8):1396-401. 
16. Carroll KK. Obesity as a risk factor for certain types of cancer. Lipids. 1998; 33(11):1055-9. 
 12 
 
17. Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: 
definitions and distinctions for health-related research. Public Health Rep. 1985; 100(2):126-31. 
18. Cecil JE, Tavendale R, Watt P, Hetherington MM, Palmer CN. An obesity-associated FTO 
gene variant and increased energy intake in children. N Engl J Med. 2008; 359(24):2558-66. 
19. Charney E. Behavior genetics and postgenomics. Behav Brain Sci. 2012; 35(5):331-58. 
20. Comuzzie AG, Blangero J, Mahaney MC, et al. Major gene with sex-specific effects 
influences fat mass in Mexican Americans. Genet Epidemiol. 1995; 12(5):475-88. 
21. De Geus EJC, De Moor MHM. Genes, Exercise, and Psychological Factors. In: Bouchard C, 
Hoffman EP, editors. Genetic and Molecular Aspects of Sport Performance. Hoboken, NJ: 
Wiley-Blackwell; 2011, p. 294-305. 
22. Degler CN. In Search of Human Nature: The Decline and Revival of Darwinism in American 
Social Thought. New York: Oxford University Press; 1992.  416 p. 
23. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006; 
444(7121):881-7. 
24. Ditschuneit HH, Flechtner-Mors M, Johnson TD, Adler G. Metabolic and weight-loss effects 
of a long-term dietary intervention in obese patients. Am J Clin Nutr. 1999; 69(2):198-204. 
25. Donnelly JE, Blair SN, Jakicic JM, et al. American College of Sports Medicine Position 
Stand. Appropriate physical activity intervention strategies for weight loss and prevention of 
weight regain for adults. Med Sci Sports Exerc. 2009; 41(2):459-71. 
 13 
 
26. Eriksson M, Rasmussen F, Tynelius P. Genetic factors in physical activity and the equal 
environment assumption-- the Swedish young male twins study. Behav Genet. 2006; 36(2):238-
47. 
27. Fall T, Ingelsson E. Genome-wide association studies of obesity and metabolic syndrome. 
Mol Cell Endocrinol. 2012; In Press,(Corrected proof,):doi: 10.1016/j.mce.2012.08.018. 
28. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to 
obesity: payer-and service-specific estimates. Health Aff. 2009; 28(5):w822-31. 
29. Fisher A, van Jaarsveld CH, Llewellyn CH, Wardle J. Environmental influences on children's 
physical activity: quantitative estimates using a twin design. PLoS One. 2010; 5(4):e10110. 
30. Flechtner‐Mors M, Ditschuneit HH, Johnson TD, Suchard MA, Adler G. Metabolic and 
Weight Loss Effects of Long‐Term Dietary Intervention in Obese Patients: Four‐Year Results. 
Obes Res. 2012; 8(5):399-402. 
31. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the 
distribution of body mass index among US adults, 1999-2010. JAMA. 2012; 307(5):491-7. 
32. Franks PW, Ravussin E, Hanson RL, et al. Habitual physical activity in children: the role of 
genes and the environment. Am J Clin Nutr. 2005; 82(4):901-8. 
33. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995; 333(13):853-61. 
 14 
 
34. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is 
associated with body mass index and predisposes to childhood and adult obesity. Science. 2007; 
316(5826):889-94. 
35. Hagberg JM, Rankinen T, Loos RJ, et al. Advances in exercise, fitness, and performance 
genomics in 2010. Med Sci Sports Exerc. 2011; 43(5):743-52. 
36. Hinney A, Nguyen TT, Scherag A, et al. Genome wide association (GWA) study for early 
onset extreme obesity supports the role of fat mass and obesity associated gene (FTO) variants. 
PLoS One. 2007; 2(12):e1361. 
37. Irwin ML, Yasui Y, Ulrich CM, et al. Effect of exercise on total and intra-abdominal body fat 
in postmenopausal women: a randomized controlled trial. JAMA. 2003; 289(3):323-30. 
38. Janssen I, Katzmarzyk PT, Ross R. Body mass index, waist circumference, and health risk: 
evidence in support of current National Institutes of Health guidelines. Arch Intern Med. 2002; 
162(18):2074-9. 
39. Joosen AM, Gielen M, Vlietinck R, Westerterp KR. Genetic analysis of physical activity in 
twins. Am J Clin Nutr. 2005; 82(6):1253-9. 
40. Kaprio J, Hammar N, Koskenvuo M, Floderus-Myrhed B, Langinvainio H, Sarna S. 
Cigarette smoking and alcohol use in Finland and Sweden: a cross-national twin study. Int J 
Epidemiol. 1982; 11(4):378-86. 
 15 
 
41. Kelly MA, Rubinstein M, Phillips TJ, et al. Locomotor activity in D2 dopamine receptor-
deficient mice is determined by gene dosage, genetic background, and developmental 
adaptations. J Neurosci. 1998; 18(9):3470-9. 
42. Klingberg F, Klengel S. Lesions in four parts of the basal forebrain change basic behaviour 
in rats. Neuroreport. 1993; 4(6):639-42. 
43. Lalonde L, Gray-Donald K, Lowensteyn I, et al. Comparing the benefits of diet and exercise 
in the treatment of dyslipidemia. Prev Med. 2002; 35(1):16-24. 
44. Lee AWS, Hengstler H, Schwald K, et al. Functional Inactivation of the Genome-Wide 
Association Study Obesity Gene Neuronal Growth Regulator 1 in Mice Causes a Body Mass 
Phenotype. PloS one. 2012; 7(7):e41537. 
45. Lee AWS, Hengstler H, Schwald K, et al. Functional Inactivation of the Genome-Wide 
Association Study Obesity Gene Neuronal Growth Regulator 1 in Mice Causes a Body Mass 
Phenotype. Plos One. 2012; 7(7):e41537. 
46. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered 
body weight. N Engl J Med. 1995; 332(10):621-8. 
47. Levine JA, Eberhardt NL, Jensen MD. Role of nonexercise activity thermogenesis in 
resistance to fat gain in humans. Science. 1999; 283(5399):212-4. 
48. Lightfoot JT. Current understanding of the genetic basis for physical activity. J Nutr. 2011; 
141(3):526-30. 
 16 
 
49. Lightfoot JT, Turner MJ, Daves M, Vordermark A, Kleeberger SR. Genetic influence on 
daily wheel running activity level. Physiol Genomics. 2004; 19(3):270-6. 
50. Lightfoot JT, Turner MJ, Pomp D, Kleeberger SR, Leamy LJ. Quantitative trait loci for 
physical activity traits in mice. Physiol Genomics. 2008; 32(3):401-8. 
51. Loos RJF, Lindgren CM, Li S, et al. Common variants near MC4R are associated with fat 
mass, weight and risk of obesity. Nat Genet. 2008; 40(6):768-75. 
52. MacLean L, Rhode B. Does Genetic Predisposition Influence Surgical Results of Operations 
for Obesity? Obes Surg. 1996; 6(2):132-7. 
53. Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight 
and human adiposity. Behav Genet. 1997; 27(4):325-51. 
54. Maia JA, Thomis M, Beunen G. Genetic factors in physical activity levels: a twin study. Am 
J Prev Med. 2002; 23(2 Suppl):87-91. 
55. McTiernan A, Yasui Y, Sorensen B, et al. Effect of a 12-month exercise intervention on 
patterns of cellular proliferation in colonic crypts: a randomized controlled trial. Cancer 
Epidemiol Biomarkers Prev. 2006; 15(9):1588-97. 
56. Mitchell BD, Rainwater DL, Hsueh WC, Kennedy AJ, Stern MP, Maccluer JW. Familial 
aggregation of nutrient intake and physical activity: results from the San Antonio Family Heart 
Study. Ann Epidemiol. 2003; 13(2):128-35. 
 17 
 
57. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United 
States, 2000. JAMA. 2004; 291(10):1238-45. 
58. Owesson-White CA, Cheer JF, Beyene M, Carelli RM, Wightman RM. Dynamic changes in 
accumbens dopamine correlate with learning during intracranial self-stimulation. Proc Natl Acad 
Sci. 2008; 105(33):11957-62. 
59. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and 
metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002; 35(2):367-
72. 
60. Rask-Andersen M, Jacobsson JA, Moschonis G, et al. Association of TMEM18 variants with 
BMI and waist circumference in children and correlation of mRNA expression in the PFC with 
body weight in rats. European Journal of Human Genetics. 2012; 20(2):192-7. 
61. Rice T, Borecki IB, Bouchard C, Rao DC. Segregation analysis of body mass index in an 
unselected French-Canadian sample: the Quebec Family Study. Obes Res. 1993; 1(4):288-94. 
62. Royall PS, Troiano RP, Johnson MA, Kohl III HW, Fulton JE. 2008 Physical Activity 
Guideline for Americans. Washington, DC: U.S. Department of Health and Human Services; 
2008.  65 p. 
63. Salamone JD. Complex motor and sensorimotor functions of striatal and accumbens 
dopamine: involvement in instrumental behavior processes. Psychopharmacology (Berl). 1992; 
107(2-3):160-74. 
 18 
 
64. Sallis JF, Owen N, Fotheringham MJ. Behavioral epidemiology: a systematic framework to 
classify phases of research on health promotion and disease prevention. Ann Behav Med. 2000; 
22(4):294-8. 
65. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, 
and incident colorectal cancer. J Natl Cancer Inst. 1999; 91(13):1147-54. 
66. Schultz W. Reward signaling by dopamine neurons. Neuroscientist. 2001; 7(4):293-302. 
67. Sevy S, Hassoun Y, Bechara A, et al. Emotion-based decision-making in healthy subjects: 
short-term effects of reducing dopamine levels. Psychopharmacology (Berl). 2006; 188(2):228-
35. 
68. Simard B, Turcotte H, Marceau P, et al. Asthma and sleep apnea in patients with morbid 
obesity: outcome after bariatric surgery. Obes Surg. 2004; 14(10):1381-8. 
69. Simonen RL, Perusse L, Rankinen T, Rice T, Rao DC, Bouchard C. Familial aggregation of 
physical activity levels in the Quebec Family Study. Med Sci Sports Exerc. 2002; 34(7):1137-42. 
70. Slentz CA, Aiken LB, Houmard JA, et al. Inactivity, exercise, and visceral fat. STRRIDE: a 
randomized, controlled study of exercise intensity and amount. J Appl Physiol. 2005; 
99(4):1613-8. 
71. Sorensen TI, Holst C, Stunkard AJ, Skovgaard LT. Correlations of body mass index of adult 
adoptees and their biological and adoptive relatives. Int J Obes Relat Metab Disord. 1992; 
16(3):227-36. 
 19 
 
72. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796 individuals reveal 
18 new loci associated with body mass index. Nat Genet. 2010; 42(11):937-48. 
73. St Jeor ST, Brunner RL, Harrington ME, et al. A classification system to evaluate weight 
maintainers, gainers, and losers. J Am Diet Assoc. 1997; 97(5):481-8. 
74. Stunkard AJ, Foch TT, Hrubec Z. A twin study of human obesity. JAMA. 1986; 256(1):51-4. 
75. Thompson PD, Moyna N, Seip R, et al. Functional polymorphisms associated with human 
muscle size and strength. Med Sci Sports Exerc. 2004; 36(7):1132-9. 
76. Tokunaga K, Matsuzawa Y, Fujioka S, et al. PVN-lesioned obese rats maintain ambulatory 
activity and its circadian rhythm. Brain Res Bull. 1991; 26(3):393-6. 
77. Truesdale KP, Stevens J, Cai J. The effect of weight history on glucose and lipids: the 
Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2005; 161(12):1133-43. 
78. Turner MJ, Kleeberger SR, Lightfoot JT. Influence of genetic background on daily running-
wheel activity differs with aging. Physiol Genomics. 2005; 22(1):76-85. 
79. U.S. Department of Health and Human Services. Physical Activity and Health: A Report of 
the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for 
Disease Control and Prevention, and National Center for Chronic Disesae Prevention and Health 
Promotion; 1996. 
 20 
 
80. Vink JM, Boomsma DI, Medland SE, et al. Variance components models for physical 
activity with age as modifier: a comparative twin study in seven countries. Twin Res Hum Genet. 
2011; 14(1):25-34. 
81. Voelker R. Escalating obesity rates pose health, budget threats. JAMA. 2012; 208(15):1514. 
82. Walsh S, Haddad CJ, Kostek MA, et al. Leptin and leptin receptor genetic variants associate 
with habitual physical activity and the arm body composition response to resistance training. 
Gene. 2012; 510(1):66-70. 
83. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become 
overweight or obese? estimating the progression and cost of the US obesity epidemic. Obesity. 
2008; 16(10):2323-30. 
84. Willer CJ, Speliotes EK, Loos RJF, et al. Six new loci associated with body mass index 
highlight a neuronal influence on body weight regulation. Nat Genet. 2009; 41(1):25-34. 
85. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005; 82(1 
Suppl):222S-5S. 
86. World Health Organization. Global Health Risks: Mortality and Burden of Disease 
Attributable to Selected Major Risks. Geneva: World Health Organization; 2009.  62 p. 
87. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of 
the mouse obese gene and its human homologue. Nature. 1994; 372(6505):425-32. 
 21 
 
88. Zhou QY, Palmiter RD. Dopamine-deficient mice are severely hypoactive, adipsic, and 
aphagic. Cell. 1995; 83(7):1197-209. 
  
 
 
 22 
 
Chapter 2 – Literature Review 
Introduction 
 Approximately 30 - 78% (1, 10, 11, 19, 29, 44) of the variation in habitual physical activity 
(PA) is explained by genetic factors. Research has identified specific genetic polymorphisms that 
may contribute to this variation. Genetic variation primarily results from common single 
nucleotide polymorphisms (SNPs). A SNP is a mutation that alters a small part of a gene, 
specifically a single base, and this polymorphism is common in at least 1% of the population. 
There are an estimated 12 million SNPs in the human genome which account for 90% of all 
human genetic variation. Although not all the SNPs confer a functional difference, many SNPs 
are reported to predispose individuals to a certain disease or trait, and thereby SNPs are often 
used to identify associations between genetic variants (i.e. SNP) and interest of phenotype (i.e. 
weight or PA). 
  The purpose of present study is to identify the SNPs that associate with PA in the 
‘Functional SNPs Associated with Human Muscle Size and Strength (FAMuSS, NIH R01 
NS40606-02)’ dataset, where the sub-set of population (n=492) were genotyped and completed 
Paffenparger PA Questionnaire (PPAQ). Previously, Walsh et al. (64) reported leptin and leptin 
receptor genetic variants, which are renowned obesity genes that initiated the research in genetics 
of obesity (67), associate with habitual PA among European-American adults in FAMuSS cohort 
(men=111, women=131, 23.4 ± 5.4 yr, 24.4 ± 4.6 kg·m
-2
). Leptin is an adipocyte-derived 
cytokine that can act in the brain to suppress feeding and maintain energy homeostasis. Likewise, 
as one of the expected phenotypic outcomes of being physically inactive is gaining weight, it is 
not surprising that obesity genes also associate with PA levels (13, 31, 43). In fact, Bouchard has 
classified obesity genes into 5 categories (6). They are, 1) a thrifty (low metabolic rate), 2) a 
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hyperphagic (impaired appetite), 3) a low lipid oxidation (burn less fat), 4) an adipogenesis 
(accumulate more fat), 5) and a sedentary (physically inactive). As shown sedentary genotype is 
classified as one of the obesity genes, and thereby genetic variants reported to associate with 
obesity may also associate with PA. Therefore, present study investigated SNPs reported to 
associate with obesity phenotypes in Genome-Wide Association Study (GWAS) in order to 
identify sedentary genotype in FAMuSS cohort. To date, 99 SNPs are reported to associate with 
obesity phenotype in GWAS, and FAMuSS sub-study had genotype information for 9 SNPs 
among 99 SNPs. However, 3 of the SNPs were excluded as they were not consistent with Hardy-
Weinberg equilibrium, and total 6 SNPs were selected for candidate SNPs. They are 
Melanocortin 4 receptor (MC4R; T2745C; rs17782313), Transmembrane protein 18 (TMEM18; 
rs6548238), Fat mass and obesity-associated gene (FTO; rs9939609), Neuronal growth 
regulator 1 (NEGR1; rs2815752), Src homology 2 B adapter protein 1 (SH2B1; Thr484Ala; 
rs7498665), and Potassium channel tetramerisation domain containing 15 (KCTD15; 
rs11084753). 
  Among the 6 SNPs, FTO (rs9939609) and MC4R (rs17782313) are reported to associate 
with PA (13, 32, 43) in human. To date, there are no studies that examine if TMEM18 
(rs6548238), NEGR1 (rs2815752), SH2B1 (rs7498665), and KCTD15 (rs11084753) associate 
with PA in humans. However, Negr1 and its association with PA have been examined with mice 
(36).   
 
Biological Basis of Habitual Physical Activity 
Obesity genes expressed in brain and their biological plausibility to associate with PA 
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  Charney et al. (14) denotes that genes particularly prevalent in the human brain are likely 
relevant for a considerable part of human behavior. It is noteworthy that hyperphagic genotype 
and sedentary genotype, that Bouchard categorized, are the obesity genes that are expressed in 
brain. Thus, we can speculate that obesity genes that code for proteins expressed in the brain or 
neural pathways may govern behaviors (i.e. eating or PA) that predispose individuals to obesity. 
In fact, Lenard et al (38), who has extensively examined central and peripheral regulation of 
food intake and PA, propose that fundamental desire to engage in PA stems from food foraging 
behavior to prevent oneself from famine as a survival mechanism. According to Lenard et al., 
one of the fundamental neurological paradigms involved is finding a good food source, 
remembering it, and finding it again. In other words, large portions of the nervous system of 
animals and humans, including the cortex, basal ganglia, and the limbic system, are concerned 
with the procurement of food as a basic and evolutionarily conserved survival mechanism to 
defend the lower limits of adiposity. For instance, a key structure is the hippocampal formation, 
known to be involved in the formation, storage, and recall of spatial and other memories (38) 
(Figure 1).  
  Taken together, there may be inter-connection of neural pathway between energy intake 
and PA energy intake. Both genes code for proteins that function in brain to induce certain 
behavior that impact energy homeostasis. Thereby, hyperphagic obesity gene may be biological 
plausible to associate with PA. With this in mind, it is noteworthy that NEGR1, KCTD15, and 
SH2B1are categorized in the hyperphagic genotype according to Bouchard’s classification as 
they were all previously reported to associate with eating behavior (3, 61).   
 
Dopaminergic pathway and physical activity 
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 Within the central nervous system (CNS), neurotransmitters, peptides, and hormones interact to 
establish a balance between energy intake and energy expenditure, resulting in body weight 
regulation and homeostasis (45). An abundance of recent research (33, 35, 40, 41, 54)  
investigating the biological pathways that govern PA participation indicates that the 
dopaminergic pathway may play a key role. Of note, dopamine is a neurotransmitter that 
functions in the control of motor movement (58), reward (59), learning, motivation (48), and 
emotion (60).  
  The dopaminergic pathway is purported to regulate voluntary PA because of its central 
role in regulating motor movement (58) and motivational behaviors (48). Wheel running 
behavior is considered to be a measurement of voluntary PA in rodents, which is defined as 
purposeful movements that expend a significant amount of energy (35). Data from 
pharmacological experiments suggest that dopamine function in hyperactive mice is impaired 
(55, 56). Rhodes et al. (55) measured acute drug responses (cocaine) of mice that had been 
selectively bred for increased running-wheel activity. They found that psycho-stimulants such as 
methylphenidate (56) and cocaine (55), which stimulate locomotor behavior and wheel running 
in control mice, decreased wheel running in hyperactive mice. The authors concluded that the 
results suggest an association between genetically determined hyperactive wheel-running 
behavior and dysfunction in the dopaminergic neuromodulatory system. Additionally, Knab et al. 
(33) investigated differences in central mRNA expression of seven dopamine genes (Drd1, Drd2, 
Drd3, Drd4, Drd5, and tyrosine hydroxylase) between highly active C57/LJ (n=17) male mice 
and less active C3H/HeJ (n=20) male mice. They found that the high-activity C57L/J strain has 
lower expression levels of dopamine D1 receptor and tyrosine hydroxylase (an indicator of 
dopamine production) than the low-activity C3H/HeJ strain (34). Such results raise the 
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possibility that specific alterations in the dopaminergic pathway may be associated with 
differential engagement in voluntary PA.  
  Dopamine deregulation has also been postulated to contribute to the development of 
obesity and binge eating, which again supports previously noted biological plausibility of 
hyperphagic genotype to associate with PA. Data have illustrated that alterations in the D2 
dopamine receptor are linked to increased reward sensitivity in obese and binge eating 
individuals (16). Likewise, research examining obesity prone rats revealed dopamine 
deficiencies in the nucleus accumbens and dorsal striatum that were directly linked to 
hyperphagia (impaired appetite) and increased body mass (22). Also, dopamine D4 receptors are 
associated with binge eating in individuals with depression or bulimia nervosa (28, 39). In 
addition, dopamine transporter knockout mice that show chronically elevated tissue dopamine 
display increased goal-directed behavior for food reward (9).  
  In summary, dopaminergic deregulation is associated with the expression of PA, eating 
behavior, and obesity-related phenotypes. Therefore, obesity genes that have impact on the 
dopaminergic pathway would be biologically plausible to associate with PA as well.  
 
Literature Review 
Systematic search method 
  In this review of the literature, we aimed to include all studies with one or more of the 
following outcomes: gene, SNPs, exercise, and PA. We performed a PubMed Search entering the 
following search terms: ("Fat mass and obesity-associated gene" OR FTO OR rs9939609 OR 
"Melanocortin 4 receptor" OR MC4R OR rs17782313 OR "Neuronal growth regulator 1" OR 
NEGR1 OR rs2815752 OR KCTD15 OR rs11084753 OR SH2B1 OR rs7498665 OR 
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"Transmembrane protein 18" OR TMEM18 OR rs6548238) AND ("physical activity" OR PARQ 
OR PAR-Q OR "physical activities" OR "physically active" OR exercise OR exercises OR 
walking OR locomotor OR "activities of daily living"). This search yielded 122 hits. If many 
literature exists, the population characteristics emulate the FAMuSS cohorts (European 
American, 23.5 ± 0.3 yr, BMI: 24.6 ± 0.2) were prioritized for review. These prioritization 
criteria for selecting literature included adults 18 to 65 years; peer-reviewed journal articles 
published in English; main topic of the article must be ‘genetic variants and PA level’; lastly, 
systematic review recruited most subject number were prioritized. However, if no articles were 
found within human, animal study that examined locomotors activities were reviewed. If 
numerous animal study exists in animal studies, comparison between knock out animal for target 
gene and control group were prioritized over the animal studies that compared control group and 
protein administered group, as primary focus of preset study is on the gene than protein. 
   In the literature review, SNPs that showed association with PA were reviewed in the first 
section: FTO (rs9939609) and MC4R (rs17782313). In the second section, SNPs that does not 
have previous literature in PA were more extensively reviewed related to its biological 
plausibility to associate with PA: TMEM18 (rs6548238), NEGR1 (rs2815752), SH2B1 
(rs7498665), and KCTD15 (rs11084753). In each SNPs, basic information of the gene and 
protein were reviewed. Then, we introduced SNPs’ association with obesity phenotype in 
FAMuSS cohort. Subsequently, SNPs’ associations with PA phenotype in previous literature 
were reviewed. Finally, SNPs’ biological plausibility to associate with PA was reviewed via 
introducing literature that reports SNP and/or proteins’ expression in neural pathway, association 
with energy intake, and implication on dopaminergic pathway.  
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Genetic variants associate with obesity and physical activity 
Fat mass and obesity-associated gene (FTO T>A; rs9939609) 
  FTO (rs9939609) is located on the 1
st
 intron of chromosome 16q12.2. Frayling et al. 
reported FTO was mostly expressed in the brain, specifically the hypothalamus (20, 63). Jia et al. 
(26), reported that FTO protein has oxidative demethylation activity targeting the abundant N6-
methyladenosine (m
6
A) residues in RNA in vitro. In addition, they showed the partial co-
localization of FTO with nuclear speckles, which supports the notion that m
6
A in nuclear RNA is 
a major physiological substrate of FTO. Nonetheless, this proposed function of FTO provides no 
immediate clues regarding the molecular-physiological mechanism by which this gene might 
affect adiposity. Therefore, how the demethlase activity of FTO is integrated into the complex 
network of energy metabolism control remains the object of intense scientific investigation  
  In 2010, Orkunoglu-Suer et al. (47) examined MC4R (rs17782313), FTO (rs9939609), 
TMEM18 (rs6548238), NEGR1 (rs2815752), SH2B1 (rs7498665), and KCTD15 (rs11084753)  in 
FAMuSS cohort (men=321, women=475, 23.1 ± 5.5 yr, 24.4 ± 4.6 kg·m
-2
) that undertook 12-
week resistance-training program with its association with BMI and subcutaneous fat. 
Investigators choose theses SNPs because they were newly identified SNPs reported by the 
Genetic Investigation of ANthropometric Traits (GIANT) consortium. Of note, the GWA meta-
analysis that GIANT consortium conducted in 2009 by Willer et al. is the largest GWA meta-
analysis conducted to date. Orkunoglu-Suer et al. reported difference in subcutaneous fat volume 
in men carrying FTO (rs9939609) A alleles (AT/AA: n = 83; −798.35 ± 2,624.30 mm3 vs. TT: n 
= 47; 9,435.23 ± 3,494.44 mm3; P = 0.02), and it explained 4.1% of the phenotype in men. 
 Cecil et al. (13) examined 2726 Scottish children, 4 to 10 years of age, who underwent 
genotyping for FTO (rs9939609). A subsample of 75 children was examined for possible 
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association of the FTO (rs9939609) with energy expenditure. They measured total energy 
expenditure by isotope dilution, resting metabolic rate by indirect calorimetry, and PA was 
calculated as subtracting resting metabolic rate from total energy expenditure. Total energy 
expenditure was significantly greater in carriers of the A allele than in non-carriers, with a 
difference of 1160 kJ (p=0.009). Resting energy expenditure was 349 kJ greater in children who 
carried the A allele than in non-carriers (p=0.03); however, inclusion of body mass or lean body 
mass as a covariate in the regression model abolished the association between genotype and 
resting energy expenditure (p=0.216). PA-related expenditure was higher for A allele carriers 
compared to non-carriers, with a difference of 1103 kJ (p=0.02). Therefore, the investigators 
concluded that the observed difference in total energy expenditure between the genotype groups 
was primarily derived from the difference in PA-related expenditure rather than resting 
metabolic rate. 
 Tung et al. (63) reported that FTO mRNA overexpression associates with increased 
levels of the dopamine regulatory enzyme tyrosine hydroxylase. Interestingly, Knab et al. (34) 
reported that low tyrosine hydroxylase associate with hi PA level in inbred mice. Although it 
remains unclear how RNA demethylation of FTO may have affected tyrosine hydroxylase 
production, these findings supports findings of Cecil et al. that FTO (rs9939609) may associate 
with PA level. 
Melanocortin 4 receptor gene (MC4R T2745C; rs17782313) 
  The melanocortin 4 receptor gene (MC4R) is located on a single exon on chromosome 
18q22. The melanocortin ‘‘system’’ can be defined as a neural circuit comprised of cells 
expressing either pro-opiomelanocortin (POMC)-derived melanocortin receptor (MCR) agonists, 
or the melanocortin antagonist agouti-related peptide (AgRP), as well as the MCR-expressing 
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cells that are targets of these neurons. Foremost of the melanocortin-mediated functions is energy 
balance regulation as a result of MCR signaling within hypothalamic and hindbrain nuclei. The 
MC4R, a 7-transmembrane G-protein coupled receptor, is expressed on the surface of neurons 
throughout the brain and in high proportion within the hypothalamus, hippocampus, and 
hindbrain (15). MC4R can be directly activated via adrenocorticotropic hormone (ACTH) or a- 
of melanocyte-stimulating hormone (MSH), or inhibited by AgRP, via release from terminals of 
POMC or AgRP/NPY axonal projections from the ARC (15).  
  Orkunoglu-Suer et al. (47) also examined MC4R (rs17782313) in FAMuSS cohort with 
its association with obesity phenotype. They reported that the MC4R (rs17782313) was 
associated with BMI in females using a dominant model (CC/CT: n=174; 24.70±0.33 kg/m
2
, TT: 
n=278; 23.41 ± 0.26 kg/m
2
, p=0.003), and it explained 1.9% (p=0.002) of the phenotype.   
In 2005, Loos et al. (43) examined whether sequence variants in genes encoding 
neuropeptides and receptors in the arcuate and paraventricular nucleus of the hypothalamus 
contribute to variations in PA level in the QFS. They genotyped SNPs in MC4R, MC3R, 
neuropeptide-Y (NPY), neuropeptide-Y Y1 receptor (NPY Y1R), cocaine- and amphetamine-
regulated transcript (CART), agoutirelated protein (AGRP), and pro-opiomelanocortin (POMC) 
genes in 669 subjects (52±3.4 yr; offspring: 28±8.7 yr). In a 3-day activity diary, the subjects 
recorded their dominant activity every 15-min period of the day. Each activity was categorized 
into one of nine activity classes, ordered by increasing energy expenditure level (based on the 
metabolic equivalent), and was scored accordingly from 1 to 9, with 1 equating to sleep and 9 
equating to vigorous-intensity activities. Subjects carrying the homozygous MC4R (rs17782313) 
T allele reported lower PA scores than those with the CC and CT genotypes (CC: 220±20 vs CT: 
200±20 vs TT:165±24, p=0.005) . The effect was most pronounced in adults without obesity 
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(BMI<30kg·m-2) (CC: 223±19 vs CT: 185±19 vs TT:158±25, p=0.004) and young adults 
(offspring) (CC: 217±16 vs CT: 172±17 vs TT:121±24, p=0.007).  Investigators concluded DNA 
sequence variation at the MC4R gene locus contributed to the propensity to be sedentary. 
However, the authors did not adjust for multiple comparisons, thus these associations may be 
spurious (43). 
  Braun et al (7) examined the body composition of MC4R knock out (KO) mice and diet-
induced obese mice to investigate the role of melanocortin signaling in regulating the accrual of 
lean mass independent from increases in fat mass. MC4R KO mice (8-week-old male, n=13) and 
age and weight matched wild type (WT) controls (n=10) were subjected to treadmill running at 
escalating speed. Despite only mild differences in body composition, MC4R KO mice showed a 
dramatic reduction in treadmill running time and distance covered compared to WT. MC4R KO 
mice ran for less than half the time and covered only one third of the distance achieved by the 
control group. To determine if a functional deficit in skeletal muscle might be responsible for the 
poor exercise endurance phenotype of MC4RKO mice, they also measured grip strength and 
found that it was slightly increased in MC4RKO mice relative to WT mice. These data suggest 
that melanocortin signaling plays a fundamental role in determining skeletal muscle function. 
Investigators concluded that inability to achieve peak exercise-induced cardiac output underlies 
the exercise phenotype of the MC4R KO mouse. 
  As shown, FTO (rs9939609) and MC4R (rs17782313) are reported to associate with PA 
in other cohort, and also appears to have biological plausibility to associate with PA. To date, 
there are no studies that examine if TMEM18 (rs6548238), NEGR1 (rs2815752), SH2B1 
(rs7498665), and KCTD15 (rs11084753) associate with PA in humans. However, Negr1 and its 
association with PA have been examined with mice (36).  
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Genetic variants associate with obesity that is biologically plausible to affect PA level 
Neuronal growth regulator 1 (NEGR1) 
  NEGR1 is located on 16q12.2, and encodes a cell adhesion molecule of the 
immunoglobulin (Ig) superfamily that belongs to the IgLON subgroup (37). Proteins belonging 
to this family influence guidance of neurons to their appropriate targets and their activities 
depend upon the type of IgLON protein expressed by neurons. Founding members of this protein 
family are limbic system-associated membrane protein (LSAMP), a 64-68 kDa (338 amino 
acids) neuronal surface glycoprotein distributed in the cortical and subcortical regions of the 
limbic system (49). Notably, anatomy of dopaminergic pathway begins in the ventral tegmental 
area of the midbrain and connects to the limbic system via the nucleus accumbens, the amygdala, 
and the hippocampus as well as to the medial prefrontal cortex (PFC) (30). 
  Orkunoglu-Suer et al. (47) also examined NEGR1 A>G in FAMuSS cohort with its 
association with obesity phenotype. They reported that the NEGR1 A>G did not show 
association with BMI, subcutaneous fat, and their response to resistance training. However, 
GIANT consortium reported that NEGR1 A>G associate with BMI, and more importantly, 
NEGR1 has been shown to associate with PA level in vivo.  
 To characterize the function of NEGR1 for body weight control in vivo, Lee et al (36) 
generated two novel mutant mouse lines, including a constitutive NEGR1-deficient mouse line 
as well as an ENU-mutagenized line carrying a loss-of-function mutation (Negr1-I87N) and 
performed metabolic phenotypic analyses. Negr1-I87N mutants display reduced food intake. 
Also, Negr1-I87N mutants displayed overall reduction in PA as measured by the number of 
breaks in infrared beams, average speed of movements, and total distance travelled within 24 hr 
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in a photo beam-based activity monitoring system, consistent with the reduced energy 
expenditure before normalization (36). 
  NEGR1 and its association with PA may be explained via NEGR1’s influence on the 
limbic system-associated membrane protein (LSAMP). Limbic system is involved in motivation, 
emotion, learning, and memory, and is highly interconnected with the nucleus accumbens, the 
brain's pleasure center. And, these responses are heavily modulated by dopaminergic projections 
from the limbic system. Innos et al (25) investigated changes in major monoamine systems in 
mice lacking the Lsamp gene. Lsamp–/– and Lsamp+/+ mice were randomly divided into groups 
that received an injection of either saline or 5 mg/kg of amphetamine. They observed a 
significant genotype effect on the content of dopamine in dorsal striatum (F(1,19) =5.67, p <0.05),  
mesencephalon (F(1,19) =4.9, p <0.05), and prefrontal cortex (F(1,20) =8.2, p <0.01) . More 
importantly, Lsamp gene KO animals showed profound change in sensitivity to the locomotor 
and rewarding effects of amphetamine (25). In the amphetamine dose curve study, distance 
travelled was significantly influenced by genotype (F(1,40) =16.25, p <0.001), dose (F(3,40) =22.07, 
p <0.001), and genotype × dose interaction (F(3,40) =8.47, p <0.001), Lsamp–/– mice being 
significantly less sensitive to the stimulating effect of 5 mg∙kg-1 and 7.5 mg∙kg-1 of amphetamine. 
With all combined, genetic variants in NEGR1 may have impact on dopaminergic pathway via 
LSAMP alteration, which has shown to associate with PA. 
Src homology 2 B adapter protein 1 (SH2B1) 
  SH2B1 gene is located on chromosome 16p11.2. SH2B1 is a member of the SH2B family 
of adaptor proteins that includes SH2B1, SH2B2, and SH2B3. Alternative splicing gives rise to 
α, β, γ and δ isoforms of SH2B1. These multiple isoforms of SH2B1 are expressed in the brain, 
which suggests that centrally expressed SH2B1β is critical to energy homeostasis. SH2B1 
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isoforms are recruited, through their SH2 domain, to the activated form of cytokine receptor-
associated JAK tyrosine kinases and multiple receptor tyrosine kinases. Influence of SH2B1 on 
tyrosine kinases enables them to serve as an adaptor and/or scaffolding protein for multiple 
hormones and growth factors, including growth hormone, insulin, leptin, insulin-like growth 
factor-1, and nerve growth factor (50, 52, 57, 65).  
  Orkunoglu-Suer et al. (47) also examined NEGR1 A>G in FAMuSS cohort with its 
association with obesity phenotype. They reported that NEGR1 A>G was associated with less of 
a difference in subcutaneous fat volume using a dominant model after the 12-week training 
period [AG/GG (n=191): 9,813±2,250 mm
3
 vs AA (n=126) 770±2,772 mm
3
; p=0.011). This 
SNP explained 2.0% of the phenotype in women. 
  Notably, SH2B1 is a key endogenous positive regulator of leptin sensitivity. Targeted 
deletion in mice results in impaired leptin signaling and severe obesity (53). Leptin is an 
adipocyte-derived cytokine that can act in the brain to suppress feeding and maintain energy 
homeostasis. Additionally, leptin activates its receptors in the ventral tegmental area, a critical 
site for neuroadaptations to rewarding stimuli, to modulate reward-seeking behaviors. As noted 
earlier, Walsh et al (64) reported leptin and leptin receptor genetic variants associate with 
habitual PA among European-American adults in FAMuSS cohort (men=111, women=131, 23.4 
± 5.4 yr, 24.4 ± 4.6 kg·m
-2
). Likewise, Bünger et al. (8) reported that lines of mice selectively 
bred for either high or low body fat also showed large differences in circulating leptin levels in 
comparison with each other and with a control line that showed intermediate leptin levels. 
Furthermore, Girard et al. (23) investigated whether circulating leptin levels have been altered in 
mice selectively bred for high voluntary wheel‐running activity. They found that serum leptin 
levels (ng/mL; log10 transformed for analyses) were significantly lower in high-runner mice than 
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in controls. Leptin levels ranged from 1.5 to 3.5 ng/mL in HR and from 1.6 to 7.3 ng/mL in 
controls. Taken together, SH2B1 genetic variant may have a potential influence on the 
dopaminergic system via altering leptin sensitivity. Since the dopaminergic pathway has been 
identified as the putative pathway that governs PA participation, these associations may 
influence PA as well. 
Potassium channel tetramerization domain containing 15 (KCTD15) 
  KCTD15 is located on chromosome 19q13.11. In 2009, KCTD15 was identified by Hotta 
et al  in humans as a BTB domain-containing protein of unknown function (24).  
  Orkunoglu-Suer et al. (47) also examined KCTD15 G>A in FAMuSS cohort with its 
association with obesity phenotype, but did not report any association with BMI, subcutaneous 
fat, or their response to resistance training. However, GIANT consortium reported that KCTD15 
G>A associate with BMI, and more importantly, functional study that examined KCTD15 
indicates that the protein product of the gene may have influence on dopaminergic pathway.  
  Dutta et al (18) conducted an in vivo study to investigate the physiological function of 
KCTD15. They showed that KCTD15 has an inhibitory role on Wnt/β-catenin signaling path 
way, which controls communication between cells in the embryo and adult (i.e., cell proliferation 
and differentiation during development and healing) (42). As previously noted, the dopaminergic 
pathway is the putative biological pathway that modulates motivation to engage in PA. 
Interestingly, studies have shown that activation of the Wnt/β-catenin pathway contributes to 
increased dopamine neurogenesis during development. That is, β-catenin promotes midbrain 
dopaminergic neurogenesis in vivo (27) and the stabilization of β-catenin in ventral 
mesencephalic precursors leads to an increase in dopamine differentiation (12, 62). While there 
is insufficient literature examining the functional relevance of KCTD15 and obesity, the 
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influence of KCTD15 on dopamine neuron via the Wnt/β-catenin pathway may have an 
implication on previous findings by GIANT consortium (66) with KCTD15 genetic variants and 
BMI. That is, genetic variants in KCTD15 gene may alter differentiation of dopamine neuron via 
Wnt/β-catenin pathway, which may eventually influence an individuals’ reward or pleasure from 
energy intake (i.e., eating) or energy expenditure (i.e., PA).  
Transmembrane protein 18 (TMEM18) 
Although previously noted SNPs have been reported to associate with energy intake or 
eating behavior, Rask-Andersen et al (51) reported that TMEM18 does not associate with eating 
behavior. However, due to its association with dopaminergic pathway, it was selected as the 
candidate SNP. 
 The TMEM18 gene is located on chromosome 2p25.3, and it codes for a highly 
conserved transmembrane protein containing three membrane-spanning regions containing a 
nuclear localization signal at the C-terminal (2). It most likely localizes to the nuclear membrane 
after translation, and was discovered to be involved in the migration of neural stem cells (2).  
Rask-Andersen et al (51) used a rodent food choice paradigm to identify associations 
between hypothalamic gene expression levels and food intake, as well as body weight of rats 
(n=36, 10 wk old). They observed no correlation for TMEM18 expression with high-fat diet 
preference, amount of chow, amount of total food ingested, or body weight in the hypothalamus, 
nucleus accumbens, amygdala or hippocampus. They also conducted linear regression analysis 
of mRNA expression of TMEM18 in regions of the brain in rats as measured by quantitative 
reverse transcriptase PCR. They reported a strong correlation (r=0.5694, p=0.0003) between 
TMEM18 expression and body weight in the rats’ prefrontal cortex (PFC).  
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The PFC has been proposed to have an important role in integrating behavioral cues from 
multiple sources in the brain (46). In particular, the dopamine neurons in the ventral tegmental 
area and PFC are thought to be very important in the reward-driven behavior-induced process by 
the drugs of addiction (4, 5). Evidence has shown that the firing activities of tegmental area 
dopamine neurons and addictive behavior of the animals are believed to be controlled by the 
glutamatergic synaptic inputs from PFC (17, 21).  Involvement of TMEM18s in neural migration 
may be a valuable lead, pointing to a role in the development of the PFC. That is, altered PFC 
neural development due to a TMEM18 genetic variant may influence the dopaminergic pathway.  
 
Conclusion 
  Genetic variants that associate with obesity may be appropriate candidate genes to further 
investigate for their association with habitual PA level. Present study hypothesized that six SNPs 
reported to associate with obesity in GWAS would also associate with PA level in FAMuSS 
cohort. Among the six SNPs, MC4R (rs17782313) and FTO (rs9939609) are previously reported 
to associate with PA level. Although TMEM18 (rs6548238), NEGR1 (rs2815752), SH2B1 
(rs7498665), and KCTD15 (rs11084753) have not been investigated with its association with PA 
in human, existing literature that examined the function of these SNPs or protein the gene codes 
for indicate that these SNPs have biological plausibility to associate with PA.
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Figure 1. Major mechanisms and factors determining energy balance (38) 
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Figure 2. Highly simplified schematic diagram showing the multiple neural systems and pathways controlling food intake, energy expenditure, and 
energy balance, with emphasis on interactions between metabolic, cognitive, and rewarding brain systems (38) 
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Chapter 3 – Methods 
Overview 
 This substudy is part of a larger study entitled, Functional Single Nucleotide Polymorphisms 
Associated with Human Muscle Size and Strength (FAMuSS, NIH R01 NS40606-02). FAMuSS 
is the first systematic study to examine how physiological responses to resistance training are 
modified by genes and the environment (11). The FAMuSS database consists of 1219 individuals 
(509 males, 708 females) between the ages of 18 to 39 yr who were genotyped for over 400 
single nucleotide polymorphisms (SNPs). This substudy is comprised of 535 young, normal 
weight men and women [23.4±0.2 yr; body mass index (BMI): 24.6±0.2 kg∙m-2] who completed 
the Paffenbarger Physical Activity Questionnaire (PPAQ) (9). FAMuSS was conducted by the 
Exercise and Genetics Collaborative Research Group consisting of researchers from the 
University of Connecticut, Dublin City University, University of Massachusetts, Central 
Michigan University, University of Central Florida, Florida Atlantic University, West Virginia 
University, Yale University, Hartford Hospital, and the Children's National Medical Center. The 
institutional review boards from the ten institutions involved with FAMuSS approved the study 
protocol.   
  The experimental design of FAMuSS has been described elsewhere (8, 10-12). The 
purpose of this study is to identify genetic variants associated with PA that have already been 
identified to associate with obesity in genome wide association studies (GWAS) (4).  
 
Subjects 
 Potential study participants were recruited from the eight resistance training sites via strategic 
flyer placement and in-house listserv and radio announcements. Subjects were excluded if they 
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were: <18 or >40 yr old, if they were taking any medications known to affect skeletal muscle 
function such as corticosteroids, antihypertensive or anti-lipidemic medications, anabolic 
steroids, diuretics, arthritis medications (Vioxx, Celebrex), Depo-Provera contraceptive 
injection, nasal inhalers (Clenbuterol and Rhinocort), lithium, or chronic use of non-steroidal 
anti-inflammatory drugs. In addition, individuals who reported regular participation in resistance 
training within the past 12 months prior to enrollment or performed occupational or recreational 
PA that involved heavy use of the upper body were also excluded.  
As part of the enrollment process subjects completed the PPAQ (Appendix A) and had their 
height (in) and body weight (lbs) measured to calculate BMI (kg·m
-2
).  FAMuSS participants 
completed the PPAQ and were genotyped for the SNPs Melanocortin 4 receptor (MC4R; 
T2745C; rs17782313), Transmembrane protein 18 (TMEM18; rs6548238), Fat mass and 
obesity-associated gene (FTO; rs9939609), Neuronal growth regulator 1 (NEGR1; rs2815752), 
Src homology 2 B adapter protein 1 (SH2B1; Thr484Ala; rs7498665), and Potassium channel 
tetramerisation domain containing 15 (KCTD15; rs11084753). Subjects who were genotyped for 
above SNPs comprised a sample of 492 individuals (230 males, 265 females) for this sub-study.  
 
Body Composition 
 Anthropometric measures were collected using standardized protocols among the testing sites. 
Height and weight were measured using a calibrated wall-mounted stadiometer and scale, 
respectively, from which BMI was calculated (kg∙m-2).  
 
Physical Activity 
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Subjects completed the PPAQ during their initial visit to assess weekly PA over last year. The 
PPAQ is a validated eight-item instrument used to measure self-reported weekly duration and 
intensity of PA (6). The PA phenotypes reported in this study were those that showed statistical 
significant associations with the genotypes. The extracted PPAQ phenotypes were: total PA 
index (kcal∙wk-1), energy expended in moderate and vigorous intensity PA (kcal∙wk-1), energy 
expended in sport or recreation (kcal∙wk-1), and time spent in light, moderate, and vigorous 
intensity PA, and sitting (hr∙wk-1). The PA phenotypes derived from the PPAQ questionnaire is 
described in greater details in Appendix C. 
 
Selection of Genetic Variants  
 As one of the expected phenotypic outcomes of being physically inactive is gaining weight, 
SNPs reported to associate with obesity phenotype in GWAS may also associate with habitual 
PA among FAMuSS cohort. Thus, the purpose of this sub-study was to examine all SNPs 
reported in GWAS published to date that associate with obesity phenotypes, and that were 
genotyped in the FAMuSS data set. To this end, we used the systematic search strategy of Fall 
and colleagues (2012) and expanded the date of their systematic search (2012/03/01). Their 
search terms included: (‘‘Genome-Wide Association Study’’ [Mesh] OR ‘‘genome wide’’ OR 
‘‘whole-genome’’) AND (‘‘Obesity’’ [Mesh] OR ‘‘Body Mass Index’’ [Mesh] OR ‘‘Body Fat 
Distribution’’ [Mesh] OR ‘‘Metabolic Syndrome X’’ [Mesh] OR ‘‘Waist–Hip Ratio’’ [Mesh] 
OR ‘‘Waist Circumference’’ [Mesh] OR ‘‘waist circumference’’ OR ‘‘body fat percentage’’ OR 
‘‘fat mass’’) with the limits: Humans, English and Publication Date from 2006/01/01 to 
2012/03/01. They have previously identified 99 SNPs that associated with obesity phenotypes, 
and no additional SNPs were reported to associate with obesity phenotype.  
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Of the 99 SNPs identified by Fall et al. (2012), FAMuSS had genotype information on six of 
these SNPs that included are included in this substudy: MC4R (rs17782313) and FTO 
(rs9939609), TMEM18 (rs6548238), NEGR1 (rs2815752), SH2B1 (rs7498665), and KCTD15 
(rs11084753)  (Table 1).  
 
Table 1.  Chi-square (χ2) and allelic frequencies of single nucleotide polymorphisms examined in 
the current study. 
 
Nearest Gene RefSeq# Alleles(+/-) χ2 p q p-value 
FTO  rs9939609 T/A 0.74 0.40 0.60 0.39 
MC4R  rs17782313 T/C 0.04 0.21 0.79 0.83 
NEGR1  rs2815752 A/G 0.71 0.65 0.35 0.39 
SH2B1  rs7498665 A/G 0.04 0.61 0.39 0.84 
KCTD15  rs11084753 G/A 0.02 0.66 0.34 0.88 
TMEM18  rs6548238 C/T 0.08 0.82 0.18 0.78 
FTO, Fat mass and obesity-associated gene; Melanocortin 4 receptor, MC4R; Neuronal growth 
regulator 1, NEGR1; Potassium channel tetramerisation domain containing 15, KCTD15; Src 
homology 2 B adapter protein 1, SH2B1; Transmembrane protein 18, TMEM18 
df=1 for all analyses. 
a
 p-value <0.05
 
= Not consistent with Hardy-Weinberg equilibrium. 
 
 
 Genotyping  
 A sample of whole blood was obtained from each subject, refrigerated, and sent to the 
Children’s National Medical Center Research (Washington, DC) where the DNA was extracted 
using the Puregene Whole Blood DNA Isolation kit (Gentra Systems, Inc., MN). Genomic DNA 
was isolated from peripheral blood lymphocytes with the Gentra Puregene DNA extraction kit 
(Qiagen, Valencia, CA) and genotyping was completed using Taqman assays from ABI (Foster 
City, CA) according to the manufacturer’s instructions (see Table 2 for assay IDs). Both alleles 
for each genetic variant were detected simultaneously using allele-specific oligonucleotides 
labeled with different fluorophores. Allele-specific PCR reactions for each polymorphism 
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included 20 ng genomic DNA, 900 nM forward and reverse PCR primers, 200 nM fluorescent 
allele discrimination probes (common allele FAM labled; rare allele VIC labeled) and TaqMan® 
Universal PCR Master Mix, No AmpErase® UNG (Applied Biosystems, Foster City, CA, USA) 
in a final volume of 25 μl. The PCR and fluorescent ratio profile was generated after 10 minutes 
at 95°C (denaturation), 44 cycles of 15 seconds at 92°C and 1 minute at an annealing 
temperature of 60°C. The end point fluorescent readings were analyzed using an ABI 7900HT 
and the two alleles are called using Sequence Detection System (SDS V 2.3 software; Applied 
Biosystems, Foster City, CA) and checked manually. The common allele frequencies for our 
population of European-derived Americans were very similar to the allele frequencies reported in 
the HapMap (7) (Table 3).  
 
Table 2. Genotyping assays for GWAS-discovered obesity susceptibility SNPs 
 
Nearest gene RefSeq#  Assay ID
 a
 
FTO  rs9939609  C__30090620_10 
MC4R  rs17782313  C__32667060_10 
NEGR1  rs2815752  C__26668839_10 
SH2B1 rs7498665  C__25999166_10 
KCTD15  rs11084753  C__31497814_10 
TMEM18  rs6548238  C__29311887_10 
FTO, Fat mass and obesity-associated gene; Melanocortin 4 receptor, MC4R; Neuronal growth regulator 
1, NEGR1; Potassium channel tetramerisation domain containing 15, KCTD15; Src homology 2 B 
adapter protein 1, SH2B1; Transmembrane protein 18, TMEM18; GWAS, genome-wide association 
study; SNP, single-nucleotide polymorphism. 
a
 From Applied Biosystem website    
 
Data Administration 
 Data from all FAMuSS investigative sites were compiled in a Health Insurance Portability and 
Accountability Act compliant master database maintained by a statistical consultant at the 
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Children's National Medical Center (Washington, DC). Each investigative site manually entered 
the FAMuSS data via a secure intranet using a confidential username and password. The PPAQ 
from each site was transferred to the University of Connecticut and entered by trained research 
assistants into a web-based data entry form 
(http://www.education.uconn.edu/surveys/paffenbarger/index2.cfm).  For each subject PA 
phenotypes were calculated using standard procedures (Appendix A). Any discrepancies that 
arouse during data entry of the PPAQ were noted and discussed at weekly research meetings. 
Solutions for correcting data were determined by group consensus and the data entry protocol 
was amended with the changes.   
  For example, there were occasions when a less common sport or activity was listed in 
question four of the PPAQ. Some activities were not listed in the PA Compendium (1) and 
therefore did not have a MET value. A MET value, as previously discussed, is necessary for 
calculating the PA phenotypes. In these situations, a similar sport or activity that does appear in 
the PA Compendium was used as a substitute. Examples of reported sports/activities not found in 
the PA Compendium included dodge ball, Tae Bo, and Dance Dance Revolution. Acceptable 
substitutions were determined as racquetball and in the last two examples, “hi-impact aerobics.” 
A complete list of substitutions can be found in Appendix B. 
 
Statistical Analysis   
 Descriptive statistics were calculated for all study variables. Hardy Weinberg Equilibrium was 
determined using χ2. Linkage disequilibrium was assessed with r2 to measure pairwise 
differences between each pair of SNPs (Table 3), and no SNPs was in linkage disequilibrium 
with the other (r
2
 <0.001). Multivariate analyses of covariance (ANCOVA) tested differences 
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among genotypes and PA phenotypes with gender and weight status (normal weight: 
BMI<25kg·m
-2
; overweight: BMI≥25kg·m-2) as fixed factors and age as a covariate. A gender × 
genotype interaction was found with rs2815752 (NEGR1) (p = 0.08), so results are presented for 
the total sample and by gender. A weight status × genotype interaction was found with 
rs17782313 (MC4R) (p = 0.078) and rs11084753 (KCTD15) (p = 0.055), so results are presented 
for the total sample and by weight status. Finally, a gender × weight status × genotype 
interaction was observed with rs9939609 (FTO) (p = 0.048), thus results are presented for total 
sample and by weight status among men.  
 When significant main effects were found from the linear multivariate tests (multivariate 
ANCOVA), post hoc analyses were performed with Bonferroni adjustments for multiple 
comparisons. For these statistical tests, if the homozygous minor group showed a statistically 
different phenotype outcome with the heterozygous group and/or homozygous major group, they 
were grouped as a recessive model (e.g. T>A, TT/AT vs TT). However, if the homozygous 
major group showed a statistically different phenotype outcome with the heterozygous group 
and/or homozygous minor group, they were grouped as a dominant model (e.g. T>A, TT vs 
AT/TT) (5). The percent variation attributable to genotype was calculated by comparing the full 
model [genotype and clinical characteristics (i.e. age, BMI, and gender)] with the constrained 
model (clinical characteristics only). The likelihood ratio test was used to test for significance of 
these models with linear regression analyses. Only the SNPs that showed statistically significant 
associations were presented in the result section.  
 Epistatic or gene interactions 
 
  In order to assess the epistatic or gene x gene interactions on habitual PA, we created an 
obesity effect allele score based upon previous GWAS obesity effect alleles reported in the 
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literature (4) (Table 2). We then computed a genotype combination score by summing obesity 
effect allele to approximate tertiles of the FAMuSS cohort as 1-4 obesity effect allele (n=153; 
33.5%), 5-6 obesity effect allele (n=173; 37.9%), and 7-10 obesity effect allele (n=131; 28.7%). 
Out of 492 FAMuSS participants in this substudy, 457 subjects were completely genotyped for 
all six SNPs and were included in this analysis.  
  Multivariate ANCOVA tested differences among obesity effect allele groups and PA 
phenotypes with gender and weight status as fixed factors and age as a covariate. A gender × 
obesity effect allele group interaction was found with kcal∙wk-1 spent in vigorous intensity PA, 
so results are presented by gender. When significant main effects were found for the linear 
multivariate tests above (multivariate ANCOVA), post hoc analyses were performed, with 
Bonferroni adjustments applied for multiple comparisons. All analyses were performed using the 
Statistical Package for the Social Sciences (SPSS) 14.0 for Windows (Chicago, IL, USA) with 
the likelihood ratios test as the exception. This analysis was performed with Statistical Analysis 
System (SAS) 9.1.3 for Windows (Cary, NC, USA). Statistical significance was established with 
alpha set as <0.05. 
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Table 3. Genotype frequencies of SNPs for participants in FAMuSS 
Gene RefSeq# 
Alleles 
(+/-) 
Obesity 
effect 
allele
a
 
Obesity effect allele 
Frequency in FAMuSS 
(+) 
Published obesity effect 
allele frequency for 
CEU (+)
b
 
MC4R rs17782313  T/C T 0.790 0.735 
TMEM18 rs6548238 C/T C 0.824 0.850 
FTO rs9939609 T/A A 0.395 0.460 
NEGR1 rs2815752 A/G A 0.650 0.637 
SH2B1 rs7498665 A/G G 0.392 0.381 
KCTD15 rs11084753 G/A G 0.664 0.690 
CEU, European Caucasian; SNPs, single-nucleotide polymorphisms; FAMuSS, Functional SNPs Associated with Muscle Size and 
Strength; CEPH, Center for the Study of Human Polymorphisms; HapMap, haplotype map 
MC4R, Melanocortin 4 receptor; TMEM18, Transmembrane protein 18; FTO, Fat mass and obesity-associated gene; NEGR1, 
Neuronal growth regulator 1 ; SH2B1, Src homology 2B adapter protein1; KCTD15, Potassium channel tetramerisation domain 
containing15 
a
According to Willer et al. (13). 
b
Utah residents with northern western European ancestry from the CEPH collection used in 
HapMap 
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Appendix C. Description of PPAQ phenotypes 
Distance walked per week (mile∙wk-1) 
Question one was used to calculate distance walked per week. Question one asks “how many city 
blocks or their equivalent do you normally walk each day?” (12 blocks = 1 mile). Thus, the 
reported distance walked per week (in miles) was calculated by multiplying the number of blocks 
walked per day by seven and divided by 12.  
 
Total PA index (kcal∙wk-1) 
The PA index was derived from questions one, three and four. Question one determined the 
calories expended per week by walking. The total number of blocks walked per week was 
multiplied by eight to calculate the caloric expenditure (kcals) (1 block = 8 kcal) (9).  Question 
three asks, “how many flights of stairs do you climb up each day?” (1 flight= 10 steps). The 
calories expended per week by stair climbing was calculated by multiplying the total flights per 
week (flights per day x 7) by four (1 flight of stairs = 4 kcal) (9). Question four asks subjects to 
“list any sports or recreation you have actively participated in during the past year. It also asks 
subjects to describe for each activity the number of times per year they have participated, the 
average time spent per bout and years of participation.  Each activity listed in question four was 
cross-referenced with the PA compendium (2) to determine its absolute intensity, expressed as 
metabolic equivalent (MET) value. Intensity can vary across activities and sports and are usually 
not objectively measured in habitual PA. The compendium assigns the activity an intensity unit 
(MET), which can then be used to estimate the caloric expenditure (kcals) associated with it. A 
MET is described as the energy expended during quiet rest and for an adult expressed as 3.5 mL 
of oxygen·kg
-1 
body weight·min
-1
 (1). This estimation is based on a 70 kg man and thus, may not 
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accurately reflect the caloric expenditure for a woman or individuals with a different body 
weight. Therefore a correction factor can be used to improve precision (1). Using this 
information, calories expended per week in each of the activities listed in question four was 
calculated using the following equation:  
 MET value x 1.225 x total minutes x times per yr/52(days/wk) (3)  
Thus, the PA index was calculated by combining total calories expended walking, climbing 
stairs, and activities listed in question four.    
 
Energy expended in moderate and vigorous intensity PA (kcal∙wk-1)  
Activities listed in question four with a MET value ranging from three to six determined the 
calories expended per week performing moderate intensity PA. All activities listed in question 
four with a MET value greater than six determined the calories expended per week while 
performing vigorous intensity PA. Calories expended per week performing vigorous and 
moderate, and sporting activity were calculated using the same methods and equation described 
above.   
 
Energy expended in sport or recreation (kcal∙wk-1) 
All of the activities listed in question four, regardless of their MET value, were used to determine 
the calories expended per week for sport or recreation activity. 
 
Time spent in light, moderate, and vigorous intensity PA, and sitting (hr∙wk-1) 
 The time spent per week performing vigorous, moderate and light intensity PA as well as time 
spent sitting were determined by question eight. Subjects were asked to enter the amount of time 
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spent per typical week day and weekend day in each of the four categories. The reported amount 
of time in each category must add up to 24 hrs for both weekday and weekend. For question 
eight the PPAQ equates vigorous intensity activity to “digging in garden, strenuous sports, 
jogging, aerobic dancing, sustained swimming, brisk walking, heavy carpentry, bicycling on 
hills, etc.” Moderate intensity activity is equivalent to “housework, light sports, regular walking, 
golf, yard work, lawn mowing, painting, repairing, light carpentry, ballroom dancing, bicycling 
on level ground, etc.” Light intensity activity is equivalent to “office work, driving a car, 
strolling, standing with little motion, etc.”  Lastly, sitting activity included “eating, reading, desk 
work, watching TV, listening to radio, etc.”  
The hours per day spent in vigorous, moderate, light intensity PA and sitting activity were 
converted to hours per week using the following equations: 
Time spent/wk performing vigorous activity = (hours/weekday∙5) + (hours/weekend day∙2) 
Time spent/wk performing moderate activity = (hours/weekday∙5) + (hours/weekend day∙2) 
Time spent/wk performing light activity = (hours/weekday∙5) + (hours/weekend day∙2) 
Time spent/wk sitting = (hours/weekday∙5) + (hours/weekend day∙2) 
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Chapter 4 Results 
Overview 
To date, there are 99 genetic variants reported to be associated with the obesity phenotype in 
genome wide association studies (GWAS) (3). The present substudy derived from Functional 
Single Nucleotide Polymorphisms Associated with Human Muscle Size and Strength (FAMuSS, 
NIH R01 NS40606-02) had genotype information for six of these SNPs: Melanocortin 4 
receptor (MC4R; T2745C; rs17782313), Transmembrane protein 18 (TMEM18; rs6548238), Fat 
mass and obesity-associated gene (FTO; rs9939609), Neuronal growth regulator 1 (NEGR1; 
rs2815752), Src homology 2 B adapter protein 1 (SH2B1; Thr484Ala; rs7498665), and 
Potassium channel tetramerisation domain containing 15 (KCTD15; rs11084753). These six 
variants were tested for associations with PA phenotypes among the FAMuSS cohort.  
Subject Characteristics   
  The sample consisted of healthy, young, normal weight European-American men and women 
[Table 1]. While age did not differ by sex (p≥0.05), men had a higher body mass index (BMI) 
than women (p<0.001). The sample’s voluntary PA level of 1633.4 ± 102.3 kcal·wk-1 was in the 
range recommended by the American College of Sports Medicine for weight gain prevention (2). 
In addition, the self-reported sitting time of 6.4 hr∙wk-1 or 40% of waking time among this 
FAMuSS subsample was slightly lower than the average American adults’ sitting time (i.e. 60% 
of waking time) (1).  
Obesity Genotype and PA Energy Expenditure Phenotype (kcal·wk
-1
) Associations  
 Three of the six SNPs associated with the PA energy expenditure phenotypes (kcal·wk
-1
) [Table 
2]. Specifically, subjects who were normal weight (BMI<25kg·m
-2
) carrying the MC4R 
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T allele reported expending 1981.2 ± 741.7 kcal∙wk-1 less than non-carriers in the total PA index 
(p=0.008), 1825.9 ± 650.2 kcal∙wk-1 less in sports and recreation (p=0.027), and 1231.3 ± 552.7  
kcal∙wk-1 less in vigorous intensity PA (p=0.005). The MC4R (rs17782313) T allele explained 
1.4 % (p=0.037) of the variability in the total PA index, 1.4% (p=0.035) in sports and recreation, 
and 0.7% (p=0.141) in vigorous intensity PA among subjects who were normal weight. 
   Subjects carrying the TMEM18 (rs6548238) C allele reported expending 1216.5 ± 356.3 
kcal∙wk-1 less than non-carriers in moderate intensity PA (p=0.001). The TMEM18 C allele 
explained 0.9% (p=0.037) of the variability in moderate intensity PA. 
Table 1. Subject Characteristics and Self-reported Physical Activity Levels 
Characteristics 
Total Sample 
(n=495) 
Women 
(n=265) 
Men 
(n=230) 
   Age (yr) 23.5 ± 0.3 23.2 ± 0.4 23.9 ± 0.4 
   BMI (kg·m
-2
)
 a
 24.6 ± 0.2 23.9 ± 0.3 25.4 ± 0.3 
 
PA phenotype 
   Total PA Index (kcal·wk
-1
) 2845.5 ± 117.5 2779.0 ± 138.7 2921.9 ± 196.0 
   Sports and Recreation (kcal·wk
-1
) 1633.4 ± 102.3 1621.5 ± 127.1 1647.0 ± 164.7 
   Vigorous Intensity PA (kcal·wk
-1
) 1008.6 ± 86.5 937.3 ± 97.4 1090.4 ± 148.6 
   Moderate Intensity PA (kcal·wk
-1
) 542.7 ± 47.6 622.2 ± 75.8 451.5 ± 53.3 
   Vigorous Intensity PA (Hr·wk
-1
) 8.2 ± 0.4 8.2 ± 0.4 8.2 ± 0.6 
   Moderate Intensity PA (Hr·wk
-1
) 20.8 ± 0.6 21.1 ± 0.8 20.6 ± 0.9 
   Light Intensity PA (Hr·wk
-1
)  36.7 ± 0.7 37.4 ± 0.9 35.8 ± 1.1 
   Sitting (Hr·wk
-1
) 44.7 ± 0.82 43.9 ± 1.0 45.5 ± 1.6 
Values are presented as mean ± standard error  
BMI, body mass index; PA, Physical activity 
a 
p=0.001 (Women
 
vs Men) from independent t-tes 
 77 
 
  Men who were overweight (BMI≥25kg·m-2) and homozygous for the FTO (rs9939609) T 
allele reported expending 871.4 ± 397.1 kcal∙wk-1 less than A allele carriers in vigorous intensity 
PA (p=0.031). The FTO T allele explained 4.8% (p=0.028) of the variability in vigorous 
intensity PA among men who were overweight.  
 
Obesity Genotype and PA Time Phenotype (hr·wk
-1
) Associations 
 Three of the six SNPs were found to be associated with the PA time phenotypes (hr·wk
-1
) 
[Table 3]. Specifically, subjects homozygous for the SH2B1 (rs7498665) G allele reported 
spending 4.8 ± 1.9 hr∙wk-1 less than non-carriers in moderate intensity PA (p=0.013), and 5.6 ± 
2.2 hr∙wk-1 more in light intensity PA. The SH2B1 (rs7498665) G allele explained 1.7% 
(p=0.013) of the variability in time spent in moderate intensity PA, and 3.5% (p=0.034) of the 
time spent in light intensity PA. 
  Women homozygous for the NEGR1 (rs2815752) G allele reported spending 7.6 ± 2.7 
hr∙wk-1 less than A allele carriers in moderate intensity PA (p=0.006). The NEGR1 (rs2815752) 
G allele explained 2.6% (p=0.0097) of the variability in time spent in moderate intensity PA 
among women.  
  Subjects who were overweight (BMI≥25kg·m-2) and homozygous for the KCTD15 
(rs11084753) A allele reported spending 14.2 ± 4.8 hr∙wk-1 more than G allele carriers in sitting 
(p=0.004). The KCTD15 (rs11084753) A allele explained 4.7% (p=0.004) of the variability in 
time spent in sitting among subjects who were overweight. 
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Table 2. Single Nucleotide Polymorphisms Associations with the Physical Activity Energy Expenditure Phenotypes (kcal·wk
-1
) 
  
Polymorphism Phenotype Total Normal weight (BMI<25 kg·m
-2
) Overweight (BMI≥25 kg·m-2) 
MC4R          
(rs17782313)   TT/CT(n=458) CC(n=22) TT/CT(n=296) CC(n=16) TT/CT(n=162) CC(n=6) 
 
Total PA Index 
(kcal·wk
-1
) 
2818.7 ± 121.8 3770.1 ± 557.3 2966.8 ± 158.2 4948.0 ± 724.4
a 2598.2 ± 191.9 2337.2 ± 1004.8 
 
Sports and 
Recreation 
(kcal·wk
-1
) 
1607.6 ± 106.5 2456.2 ± 487.1 1680.1 ± 138.7 3506.0 ± 635.0
 b 
 852.5 ± 138.9 1057.3 ± 727.5 
 
Vigorous 
Intensity PA 
(kcal·wk
-1
) 
995.3 ± 89.9 1574.7 ± 411.2 1091.6 ± 117.9 2322.8 ± 539.8
 c
 1491.1 ± 166.0 1371.4 ± 869.5 
TMEM18  
(rs6548238)   CC/CT (n=474) TT(n=16) CC/CT(n=306) TT(n=13) CC/CT(n=168) TT(n=3) 
  
Moderate 
Intensity PA 
(kcal·wk
-1
) 
522.7 ± 51.0 1739.2 ± 352.5 d 529.3 ± 62.6 804.9 ± 304.3 522.3 ± 74.1 2236.4 ± 556.4 e 
FTO          
(rs9939609) 
 
Total Normal weight Men (BMI<25 kg·m
-2
) Overweight Men (BMI≥25 kg·m-2) 
 
TT (n=172) AA/AT (n=311) TT (n=51) AA/AT (n=77) TT (n=51) AA/AT (n=77) 
  
Vigorous 
Intensity PA 
(kcal·wk
-1
) 
962.7 ± 164.4 1066.7 ± 113.3 1492.7 ± 348.5 1175.8 ± 283.4 313.3 ± 312.8 1184.7 ± 244.3
 f
 
Values are presented as mean ± standard error adjusted for age 
BMI, body mass index; PA, Physical activity 
a
 p=0.008,
 b
 p=0.027,
 c
 p=0.005,
 d
 p=0.001,
 e
 p=0.001, and 
f
 p=0.031, (genotype vs genotype) from independent t-test adjusted for age 
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Table 3. Single Nucleotide Polymorphisms Associations with Physical Activity Time  Phenotypes (hr·wk
-1
) 
 
Polymorphism Phenotype Total Men Women 
NEGR1   
(rs2815752)   AA/AG (n=435) GG (n=56) AA/AG (n=201) GG (n=28) AA/AG (n=234) GG (n=28) 
  
Time Spent in 
Moderate PA 
(hr·wk
-1
) 
21.1 ± 0.6 16.0 ± 0.8 20.9 ±  1.0 18.1 ± 2.7 21.3 ± 0.9 13.7 ± 2.6
 a
 
SH2B1  
(rs7498665) 
 
AA/AG(n=196) GG(n=30) AA/AG(n=196) GG(n=30) AA/AG(n=217) GG(n=46) 
 
Time Spent in 
Moderate PA 
(hr·wk
-1
) 
21.3 ± 0.7 16.5 ± 1.8
 b
 21.3 ± 1.0 16.8 ± 2.6 21.9 ± 0.9 17.4 ± 1.9
 c
 
 
Time Spent in 
Light PA (hr·wk
-1
) 
35.8 ± 0.9 41.4 ± 2.1
 d
 35.3 ± 1.2 37.9 ± 3.1 36.1 ± 1.0 43.7 ± 2.2
 e
 
KCTD15  
(rs11084753) 
  Total Normal weight (BMI<25 kg·m
-2
) Overweight (BMI≥25 kg·m-2) 
 GG/AG (n=434) AA(n=56) GG/AG (n=282) AA(n=37) GG/AG (n=152) AA(n=19) 
  
Time Spent in 
Sitting (hr·wk
-1
) 
44.2 ± 0.9 48.2 ± 2.5 44.3 ± 1.1 43.3 ± 3.0 44.2 ± 1.6 58.5 ± 4.6
 f
 
Values are presented as mean ± standard error adjusted for age 
BMI, body mass index; PA, Physical activity 
 a
 p=0.006,
 b
 p=0.013,
 c
 p=0.031,
 d
 p=0.013,
 e
 p=0.002, and 
f
 p=0.004 (genotype vs genotype) from independent t-test adjusted for age 
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Obesity Effect Allele Score and Physical Activity Phenotype Associations 
  We examined associations among increasing numbers of obesity effect alleles [Table 3 in 
chapter 3] (3, 4) and PA level by calculating an obesity effect allele score [Table 4]. Among the 
457 subjects genotyped for the six SNPs reported to be associated with obesity in GWAS (3, 4) 
among the FAMuSS cohort, 33.5% of the subjects carried 1-4 obesity effect alleles, 37.9% of the 
subjects carried 5-6 obesity effect alleles, and 28.7% of the subjects carried 7-10 obesity effect 
alleles. Men carrying 5-6 obesity effect alleles expanded 1082.3 ± 447.2 more kcal∙wk-1 in sports 
and recreation (p=0.049) and 663.8 ± 418.1 more kcal∙wk-1 in vigorous intensity PA (p=0.049) 
[Figure 1] than men carrying 7-10 obesity effect alleles. In addition, men carrying 5-6 obesity 
effect alleles had a BMI that was 1.5  ± 0.5 kg∙m2 greater than men with 1-4 obesity effect alleles 
(p=0.016). The obesity effect allele score was not associated with any PA phenotypes or BMI 
among women or the total sample (p≥0.05).  
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Table 4. Obesity Effect Alleles Score Associations with Physical Activity Energy Expenditure Phenotype (kcal∙wk-1) and Body Mass Index 
  Total Men  Women 
Number of Obesity Effect 
Allele 
1-4 5-6 7-10 1-4 5-6 7-10 1-4 5-6 7-10 
n=153 n=173 n=131 n=71 n=79 n=58 n=82 n=94 n=73 
33.5% 37.9% 28.7% 15.5% 17.3% 12.7% 17.9% 20.6% 16.0% 
Phenotypes 
Total PA Index (kcal·wk
-
1
) 
2687.8 ± 212.7 3156.9 ± 199.6 2657.5 ± 229.4 2739.4 ± 362.5 3480.7 ± 342.9 2503.3 ± 409.6 2650.7 ± 281.2 2809.6 ± 250.3 2667.9 ± 285.1 
Sports and Recreation 
(kcal·wk
-1
) * 
1447.8 ± 184.9 1988.9 ± 173.5 1414.9 ± 199.4 1554.3 ± 303.3 2218.1 ± 287.0 1135.8 ± 342.8
a
 1401.4 ± 257.1 1683.6 ± 228.9 1578.7 ± 260.8 
   BMI (kg·m
-2
)
 
* 25.4 ± 0.3 26.1 ± 0.2 26.0 ± 0.3 25.3 ± 0.4 26.8 ± 0.4
b 
 25.8 ± 0.8 25.6 ± 0.4 25.4 ± 0.3 26.2 ± 0.4 
Values are presented as mean ± standard error adjusted for age 
PA, Physical activity; BMI, Body mass index 
*p<0.05, analysis from multivariate ANCOVA adjusted from age among men  
a
p=0.031, 5-6 vs 7-10 from post-hoc pair-wise comparison bonferroni adjusted following multivariate ANOCOVA 
b
p=0.016, 1-4 vs 5-6 from post-hoc pair-wise comparison bonferroni adjusted following multivariate ANOCOVA 
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Figure 1. Associations among number of Obesity Effect Allele and kcal∙wk-1 Spent in 
Vigorous Intensity Physical Activities and Other Activities 
 
 
Bar displays energy expended in vigorous intensity PA and other activities (mean±SEM). 
*p=0.031, 5-6 vs 7-10 from post-hoc pair-wise comparison bonferroni adjusted  
Age was a significant covariate in this association.  
 
 
 
* 
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Chapter 5. Discussion 
 We tested six SNPs associated with obesity from GWAS (12) for their association with 
PA in the FAMuSS cohort. These SNPs were MC4R (rs17782313) and FTO (rs9939609), widely 
reported in the obesity literature; and the newly identified SNPs (43) TMEM18 (rs6548238), 
NEGR1 (rs2815752), SH2B1 (rs7498665), and KCTD15 (rs11084753) that have not been studied 
in humans regarding their association with PA. We found these six SNPs associated with a 
variety of self- reported PA phenotypes. These associations were gender and body weight 
dependent and accounted for ~1-5% of the variance in the PA phenotypes. The genotype 
differences in energy expenditure ranged from 871 to 1981 kcal∙wk-1 and equated to potentially a 
weight gain or loss of 11-25 lb∙yr-1, suggesting our findings have important implications for 
weight maintenance.  
  We also examined gene interactions by summing the number of obesity effect alleles. 
Men with 5-6 obesity effect alleles expended 663.8 ± 418.1 more kcal∙wk-1 in vigorous intensity 
PA than men with 7-10 obesity effect alleles, with similar non-significant trends noted for 1-4 
obesity effect alleles. Also, men carrying 5-6 obesity effect alleles had a BMI that was 1.5 ± 0.5 
kg∙m2 greater than men with 1-4 obesity effect alleles, with similar non-significant trends noted 
for 7-10 obesity effect alleles. These findings suggest a co-dominant influence of obesity effect 
and non-effect alleles positively on vigorous intensity PA and negatively on BMI in the 
FAMuSS cohort. 
 Our findings with MC4R (rs17782313) and FTO (rs9939609) and their associations with 
PA confirm prior reports in the literature. Loos et al. (26) examined whether MC4R 
(rs17782313) influenced self-reported PA among parents (n=326, 52 ± 3.4 yr) and their offspring 
(n=343, 28 ± 8.7 yr) who were overweight in the Quebec Family Study. PA was recorded in a 
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three day PA diary with each activity categorized into one of nine PA classes, ranging from 
sleep=1 MET to vigorous intensity PA=9 METs. The parents who were homozygous for the 
MC4R (rs17782313) T allele reported engaging in 986.1 kcal∙wk-1 less in moderate-to-vigorous 
intensity PA than subjects with the CT genotype and 1500.6 kcal∙wk-1 less than the CC genotype, 
with these trends most pronounced in adults who were not obese. Similar to Loos et al. (26), we 
found body weight dependent associations with MC4R (rs17782313) and PA. That is, FAMuSS 
subjects who were normal weight and carried the MC4R (rs17782313) T allele reported 
expending 1981.2 ± 741.7 kcal∙wk-1 less than non-carriers in total PA, a genotype difference that 
explained 1.7 % of the variance in PA, and potentially could approximate a weight gain or loss 
of 25 lb∙yr-1.    
 Cecil et al. (8) examined 97 Scottish children, 4 to 10 years of age, for possible 
association of FTO (rs9939609) with energy expenditure. They measured total energy 
expenditure by isotope dilution, resting metabolic rate by indirect calorimetry, and PA was 
calculated by subtracting resting metabolic rate from total energy expenditure. Cecil et al. (8) 
found children carrying the FTO (rs9939609) A allele expended 160.3 kcal∙wk-1 more than non-
carriers. Similarly, we found the FTO (rs9939609) A allele associated with greater energy 
expenditure than non-carriers in the FAMuSS cohort. That is, men who were overweight and 
carried the FTO (rs9939609) A allele reported expending 871.4 ± 397.1 kcal∙wk-1 more than 
non-carriers in vigorous intensity PA, a genotype difference that explained 4.8 % of the variance 
in PA, and potentially could approximate a weight gain or loss of 11 lb∙yr-1.    
Reports in the literature and our new findings collectively support the notion that obesity-
related genetic variants are plausible candidate genes to examine for their association with PA. 
Bouchard (5) has classified obesity genes into five categories: 1) thrifty (low metabolic rate), 2) 
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adipogenesis (accumulate more fat), 3) low lipid oxidation (burn less fat), 4) hyperphagic (over 
eat), and 5) sedentary (physically inactive), demonstrating the various effects genes can have on 
obesity. Among these, hyperphagic and sedentary genes are expressed in the brain and influence 
behavior, namely energy intake and expenditure, respectively (5). 
  The six SNPs we examined have been classified as hyperphagic (3, 8, 22, 30) and are 
expressed in the brain, specifically the hypothalamus, where energy homeostasis is regulated 
(44). The hypothalamus is the primary output node for the limbic system, which is responsible 
for endocrine function and behavior reinforcement. The limbic system has been implicated in the 
control of food procurement as an evolutionarily conserved survival mechanism to defend 
against famine (23). More, Lenard et al. (23) proposed that the fundamental desire to engage in 
PA behaviors likely resides in a neural pathway nearby where energy intake is regulated. Recent 
research (17, 19, 24, 25, 32) has indicated the dopaminergic pathway may govern PA 
participation  because of its central role in motor movement (35), reward (36), learning, 
motivation (28), and emotion (37). Further, dopaminergic neurons are located primarily in the 
ventral tegmental area of the brain and the hypothalamus. Thus, the inter-connection of common 
neural mechanistic pathways between energy intake (hypothalamus) and PA (dopaminergic 
pathway) suggest genetic variants associated with obesity and other related transcriptional and 
translational regulatory factors may have associations with PA.  
  Previous studies (18-20, 33) reported neural association between dopaminergic pathway 
and PA levels. Knab et al. (17) investigated differences in the central mRNA expression of 
dopamine genes [dopamine receptor 1 (Drd1) and tyrosine hydroxylase (TH)] between highly 
active and less active male mice. They found the high-activity strain had lower expression of 
Drd1 and TH than the low-activity strain (18), meaning the highly active mice had lower 
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expression of dopaminergic genes compared to less active mice. Mc4r and Drd1 are co-
expressed in neurons located in the nucleus accumbens, part of the ventral tegmental area of the 
brain and the hypothalamus (9). Furthermore, overexpression of FTO mRNA in the 
hypothalamus is associated with increased levels of TH, an indicator of dopamine production 
(40). The common neural influence of MC4R and FTO on dopamine genes TH and Drd1 should 
be explored further for their associations with obesity and PA to provide mechanistic insight for 
the associations we observed in the FAMuSS cohort.  
  To our knowledge, this is the first study investigating NEGR1 (rs2815752), KCTD15 
(rs11084753), SH2B1 (rs7498665), and TMEM18 (rs6548238) and their associations with PA in 
humans. The biological mechanism by which these SNPs may modulate PA is largely unknown. 
However, the biological function of the proteins and their involvement in the dopaminergic 
pathway may provide insight for future investigation. NEGR1 promotes neurite growth of 
hypothalamic neurons (21), and has been shown to be associated with the limbic system 
membrane protein (LSAMP) (27). As the limbic system is largely modulated via the 
dopaminergic pathway, the influence of NEGR1 on LSAMP may have implications toward 
desire to engage in PA. Moreover, Lsamp knockout mice have been shown to display low PA 
level in response to injection of drugs containing dopamine (5 mg∙kg-1 of amphetamine) 
compared to Lsamp overexpressed mice (16).  
  KCTD15 is involved in neural crest formation via the Wnt/β-catenin signaling pathway 
(11). The Wnt/β-catenin signaling pathway influences dopamine neurogenesis (6, 38). SH2B1 
upregulates the production of leptin (34), a hormone that is involved with energy intake, which 
in turn activates its receptors in the dopaminergic pathway (13, 39). Of note, Walsh et al. (42) 
found leptin and leptin receptor genetic variants associated with self-reported PA among the 
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FAMuSS cohort. Finally, TMEM18 is involved in the migration of neural stem cells (2). In rats, 
weight gain and overexpression of TMEM18 showed association in prefrontal cortex (31), where 
the firing activities in dopamine neurons are controlled via glutamatergic synaptic input (10, 14). 
The biological functions of NEGR1, KCTD15, SH2B1, and TMEM18 suggest potential 
involvement in the dopaminergic pathway, which has also been shown to have an important role 
in PA behavior (18, 20, 33). The common central neural influence of genetic variants associated 
with obesity and PA, particularly in the dopaminergic pathway, is worthy of notice and further 
investigation. 
   Our findings with FTO (rs9939609), NEGR1 (rs2815752), SH2B1 (rs7498665) and PA 
were gender dependent. Reasons for these associations are unclear. However, estrogen promotes 
dopamine sensitivity primarily through increased firing rate of dopamine neuron in the ventral 
tegmental area (46). This heightened sensitivity in turn could influence the desire to engage in 
PA lending insight into the gender dependent association we observed. At this time, however, the 
role of estrogen in PA behavior is purely speculative due to the paucity of data exploring genetic 
variants and PA. 
We examined gene interactions among the six SNPs and their association with BMI and 
PA level in the FAMuSS cohort. We calculated the number of obesity effect alleles for six SNPs 
in our cohort that were previously identified by GWAS to associate with obesity (12). Since low 
PA level is typically associated with high BMI, we hypothesized that there would be a dose 
response decrease in PA level and increase in BMI as the number of obesity effect alleles 
increased. However, we observed a co-dominant influence of obesity effect and non-effect 
alleles on PA level and BMI. Specifically, men with 5-6 obesity effect alleles expended 663.8 ± 
418.1 more kcal∙wk-1 in vigorous intensity PA than men with 7-10 obesity effect alleles, and had 
 89 
 
a BMI that was 1.5 ± 0.5 kg∙m2 greater than men with 1-4 obesity effect alleles, with similar non-
significant trends noted for 7-10 obesity effect alleles.  
 Our findings are consistent with the work of Cecil et al. (8) who found genetic 
predispositions to high BMI, PA level, and energy intake among Scottish children. They found 
children carrying the FTO (rs9939609) A allele had 71.6 kcal∙meal-1 higher energy intake, 0.9 
kg∙m2 higher BMI, and 160.3 kcal∙wk-1 higher energy expenditure than non-carriers. According 
to the classification scheme of Bouchard (5), obesity genes predispose individuals to obesity via 
multiple pathways such as high rate of adiopogenesis, low lipid oxidation, and hyperphagia. 
Thus, if high PA level is coupled with obesity genes to offset the energy expenditure, an 
individual could express a high BMI despite engaging in more PA than other genotype groups. 
The National Weight Control Registry consists of individuals maintaining a weight loss of at 
least 13.6 kg (30 lb) for a minimum of 1 year. Although National Weight Control Registry 
entrants report an average of 2,621 kcal∙wk-1 in PA, there is considerable variability in the 
amount of PA completed, with ~25% reporting <1,000 kcal∙wk-1 and ~50% reporting > 2800 
kcal∙wk-1 (7). As shown, some may perform more PA for successful weight loss and/or 
maintenance than others, and this variability may explain the genetic predisposition to high BMI 
in spite of high PA level reported by Cecil et al. and now by FAMuSS investigators. 
   The genotype differences in energy expenditure we found that ranged from 871 to 1981 
kcal∙wk-1 could theoretically amount to a weight gain or loss of 11 to 25 lb∙yr-1. These clinically 
significant outcomes have important implications for public health (45). Furthermore, preference 
of vigorous intensity PA was observed among men who were overweight (BMI≥25kg·m-2) and 
FTO (rs9939609) A allele carriers, such that they expended 871.4 ± 397.1 kcal∙wk-1 more than 
non-carriers in vigorous intensity PA. Thus, when recommending exercise to adults for overall 
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health benefits, these exercise intensity preferences due to genotype could be considered when 
counseling people to become more physically active due to what appears to be a genetic 
predisposition to prefer vigorous over moderate intensity PA among overweight men with the 
FTO (rs9939609) A allele carriers. Nonetheless, incorporating genetic information into 
personalized exercise prescription in practice remains a vision of the future until scientists 
elucidate the complex interconnected influence of genetic factors, clinical factors, and 
environment on phenotypes of interest (15). 
 This study has several limitations. Habitual PA is a complex behavior influenced by 
many genetic factors (other than the six SNPs we examined), clinical information (age, BMI, and 
gender) and environmental factors (social, built, and natural) (4). The PA data we collected with 
the Paffenbarger PA questionnaire are susceptible to subject recall and social desirability bias 
(29). However, the Paffenbarger PA questionnaire is a valid and reliable method for assessing 
leisure time PA in similar populations to the present study (1). We also did not obtain 
mechanistic data or energy intake phenotypes such that our discussion of PA and energy intake 
mechanisms is purely speculative. This study has several strengths. We chose candidate SNPs 
from a systematic review of obesity-related genetic variants reported in GWAS that had been 
genotyped in FAMuSS (12, 44). Furthermore, FAMuSS is recognized as one of the largest 
exercise genomics studies conducted [14, 47]. Finally, PA is more heritable among young adults 
and tends to decrease with age (41). Therefore, as ~75% of the FAMuSS subjects are 18 to 25 
years of age, their PA is likely to exhibit a high level of heritability. 
 In summary, we have shown that six genetic variants associated with obesity in GWAS 
that were genotyped in the FAMuSS cohort also associated with habitual PA. These associations 
were gender and BMI dependent, and accounted for ~1-5% of variance of PA level. The 
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genotype differences in energy expenditure ranged from 871 to 1981 kcal∙wk-1 equating to a 
weight gain or loss of potentially 11-25 lb∙yr-1.  Our findings suggest a personalized approach to 
weight management is warranted based upon genetic predispositions to habitual PA engagement.  
The mechanisms explaining these associations appear to resides in similar central neural 
pathways as energy intake (i.e. the dopaminergic pathway) that should be explored further as do 
the remaining 93 obesity-related genetic variants in GWAS for their associations with obesity 
phenotypes, habitual PA level and energy intake. 
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